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ABSTRACT 
Nearly all humans acquire a human papillomavirus (HPV) infection during their lifetime. HPV 
is a necessary, but not sufficient, cause of cervical and vaginal cancer. The vast majority of 
HPV infections regress spontaneously, even the precancerous lesions (intraepithelial 
neoplasias) of the female genital tract that HPV causes. Secondary prevention of cervical 
cancer by organised screening has reduced rates by 80% in Finland and some other countries. 
Detected precancerous cervical lesions are treated with local excision or destruction, 
because the progressive or regressive nature of an individual lesion remains unknown. These 
procedures have a 90% initial cure rate but may predispose to late miscarriage or preterm 
birth in subsequent pregnancies. Prophylactic HPV vaccines targeting the two most common 
HPV types in cervical cancer (HPV 16 and 18) have been available for a little over a decade. 
A near eradication of HPV infections and precancerous lesions in adolescents has been 
demonstrated a decade after vaccination; however, the full effect of mass vaccination, 
especially on cancer rates, will only be seen decades later.  
 
Characterising the prevaccination era HPV-type distribution can aid the assessment of the 
effect of vaccinations. Sensitivity of screening will suffer greatly when disease rates decrease 
after vaccinations. However, for decades there will be both unvaccinated and vaccinated 
women in screening, and HPV-type and age-specific information can aid in refining screening 
programs. HPV-type distribution also varies geographically; therefore, we assessed the 
current types causing morbidity in Finnish women. Our study of 1279 women referred to 
colposcopy for abnormal cytology found a distinct, age-related polarisation of HPV types; 
this revealed that HPV16/18 is much more common in young women (<30 years of age) than 
in women ≥45 years of age. Histological high-grade cervical disease was diagnosed in 503 
women, and even in this group the type distribution remained polarised according to age. 
Two thirds of high-grade disease in young women were attributed to HPV16/18, whereas it 
was only found in one third of women ≥45. Other high-risk types and even HPV negativity 
were more common than HPV16/18 in high-grade disease in the older women. 
 
We performed a meta-analysis on the outcomes of untreated CIN2, because treatment of 
cervical intraepithelial neoplasia (CIN) can lead to reproductive complications, and individual 
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previous studies have shown high spontaneous regression rates of moderate lesions (CIN 
grade 2, CIN2) especially in young women. Summary estimates from 36 studies showed the 
overall regression rate at two years to be 50% and the progression rate 18%. The two-year 
regression rate was 60% and the progression rate was 11% in a subgroup analysis of women 
<30 years of age (approximately 1000 women). Overall progression to invasive cancer was 
rare (0.5%, n=15/3160). In addition, we assessed the performance of a DNA methylation 
panel (S5 classifier) in predicting progression of untreated histological CIN2 in a prospective 
cohort study of 149 women (18-30 years of age). S5 was independently able to predict 
progression even when adjusted for age, initial cytology, cigarette smoking, and HPV16/18 
status. 
 
Vaginal intraepithelial neoplasia (VAIN) is more uncommon than CIN and presents mostly in 
older women. Contemporary treatment is mostly laser vaporisation, but recurrence occurs 
in up to a third, and repeated treatments can be scarring. HPV persistence is associated with 
recurrence.  An immunomodulator imiquimod has been used in small studies with promising 
success rates. We recruited 30 women with histological high-grade VAIN into a three-arm, 
randomised trial comparing the efficacy of self-administered vaginal imiquimod, laser 
vaporisation, and expectant management. No progressions were observed during the four 
months of follow-up, and histological regression rates showed no significant differences 
between the study arms (80% in the imiquimod arm, 100% in the laser arm). HPV clearance, 
however, was significantly more common in the imiquimod arm (63%) than in the laser arm 
(11%) (p=0.05).  
 
While we wait and hope for a widespread effect of the prophylactic HPV vaccines, it still 
remains important to refine who, when, and how to treat among women afflicted by HPV-
related disease. 
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FINNISH SUMMARY 
Lähes kaikki ihmiset saavat ihmisen papilloomavirusinfektion (human papillomavirus, HPV) 
jossain vaiheessa elämäänsä. HPV on välttämätön, mutta ei riittävä, kohdunkaula- ja 
emätinsyövän aiheuttaja. Valtaosa HPV-infektioista ja jopa sen aiheuttamista syövän 
esiastemuutoksista naisen synnytyselimissä paranee ilman hoitoa. Seulonta 
sekundääripreventiona on vähentänyt 80 % kohdunkaulasyöpätapauksista Suomessa ja 
joissain muissa maissa. Todetut kohdunkaulan esiastemuutokset hoidetaan paikallisella 
kirurgisella poistolla tai tuhoamisella, koska yksittäisen muutoksen paranemista tai 
etenemistä ei voida ennustaa. Muutoksen paikallisella poistolla on 90 % ensivaiheen 
onnistumisaste, mutta se voi altistaa myöhäiselle keskenmenolle tai ennenaikaiselle 
synnytykselle tulevissa raskauksissa. Profylaktisia HPV-rokotteita, jotka kattavat 
kohdunkaulasyövän kaksi yleisintä HPV-tyyppiä (HPV16 ja 18), on ollut saatavilla hieman yli 
vuosikymmenen ajan. Tutkimuksissa vuosikymmen lapsuudessa/nuoruudessa saatujen 
rokotusten jälkeen HPV-infektioiden ja esiastemuutosten on osoitettu lähes kokonaan 
hävinneen. Väestötason rokottamisen vaikutusta etenkin syövän esiintymiseen joudutaan 
silti odottamaan vielä vuosikymmeniä. 
 
Ennen väestötasoista rokotekattavuutta on tärkeä tuntea tällä hetkellä sairastavuutta 
aiheuttavat HPV-tyypit, jotta rokotusten vaikutusta voidaan arvioida. Jatkossa seulonnan 
herkkyys tulee selvästi vähenemään, kun tautitapausten määrä pienenee. Vuosikymmenien 
ajan seulontaan tulee kuitenkin edelleen osallistumaan sekä rokottamattomia että 
rokotettuja naisia ja HPV-tyyppi- ja ikäkohtainen tieto voi auttaa parantamaan 
seulontaohjelmia. Lisäksi HPV-tyyppijakauma vaihtelee maantieteellisesti, joten arvioimme 
sairastavuutta aiheuttavia HPV-tyyppejä suomalaisissa naisissa. Totesimme 1279 
kolposkopiaan solumuutoksen vuoksi lähetetyn naisen joukossa selvän ikään liittyvän 
jakauman HPV-tyypeissä. HPV16/18 oli paljon tavallisempi nuorilla naisilla (<30-vuotiaat) 
kuin ≥45-vuotiailla. Histologinen vaikea-asteinen muutos todettiin 503 naisella, ja tässäkin 
ryhmässä tyyppijakauma oli ikäryhmissä epätasainen. Kaksi kolmasosaa nuorten naisten 
vaikeista muutoksista liittyivät HPV16/18:aan ja vain kolmasosa yli 45-vuotiaiden. 
Vanhempien naisten vaikeissa esiastemuutoksissa muut korkean riskin virustyypit ja HPV-
negatiivisuus olivat tavallisempia kuin HPV16/18. 
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 Koska esiastemuutosten (cervical intraepithelial neoplasia, CIN) hoito voi johtaa 
raskauskomplikaatioihin ja yksittäiset aiemmat tutkimukset ovat osoittaneet keskivaikeiden 
esiastemuutosten (CIN2) spontaanin paranemistaipumuksen olevan suuri etenkin nuorilla 
naisilla, teimme meta-analyysin hoitamattomien CIN2-muutosten luonnollisesta kulusta. 36 
tutkimuksesta saatu arvio näytti CIN2-muutoksen paranevan 50 % tapauksista kahdessa 
vuodessa kun taas 18 % muutoksista eteni. Vain alle 30-vuotiaita naisia sisältäneessä 
alaryhmäanalyysissä (noin 1000 naista) kahden vuoden kohdalla 60 % muutoksista parani 
kun vain 11 % eteni. Eteneminen syöväksi oli kaikkiaan harvinaista (0,5 %, n=15/3160). Lisäksi 
arvioimme DNA-metylaatioluokittelijan (S5 classifier) toimivuutta CIN2-muutoksen 
etenemistä ennakoivana tekijänä 149 nuoren (18-30-vuotiaan) naisen prospektiivisessa 
kohorttitutkimuksessa. S5 pystyi itsenäisesti ennustamaan muutoksen etenemistä iästä, 
lähtötilanteen solumuutoksen vaikeusasteesta, tupakoinnista ja HPV16/18-löydöksestä 
riippumatta. 
 
Emättimen esiastemuutokset (vaginal intraepithelial neoplasia, VAIN) ovat harvinaisempia 
kuin kohdunkaulan muutokset ja esiintyvät pääasiassa vanhemmilla naisilla. Muutoksia 
hoidetaan nykyään pääasiassa laserilla, mutta tauti uusiutuu noin joka kolmannella ja 
etenkin uusintahoidot voivat olla arpeuttavia. HPV:n säilyminen on tunnettu muutosten 
uusiutumista ennakoiva tekijä. Immuunivasteen muuntelija imikimodia on käytetty aiemmin 
joissain pienissä tutkimuksissa lupaavin tuloksin. Rekrytoimme 30 naista, joilla oli todettu 
keskivaikea tai vaikea-asteinen VAIN-muutos, satunnaistettuun tutkimukseen, jossa 
verrattiin itseannostellun imikimodin, laserhoidon ja seurannan tehoa hoidossa. Yksikään 
muutoksista ei edennyt neljän kuukauden seurannassa ja paranemisaste oli yhtäläinen 
imikimodi- ja laserhoidolla (80 % ja 100 %). HPV:n häviäminen oli kuitenkin selvästi 
tavallisempaa imikimodiryhmässä (63 %) kuin laserryhmässä (11 %) (p=0.05). 
 
Profylaktisten HPV-rokotusten laajaa vaikutusta odottaessa ja toivoessa on edelleen tärkeää 
tarkentaa keitä naisia, milloin ja miten hoidetaan HPV:n aiheuttamissa sairauksissa. 
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ABBREVIATIONS 
AGC-FN atypical glandular cells favor neoplasia 
AGC-NOS atypical glandular cells not otherwise specified 
AIS adenocarcinoma in situ 
APC antigen presenting cell 
ASC-H atypical squamous cells, cannot rule out HSIL 
ASC-US atypical squamous cells of undetermined significance 
AUC area under the receiver operating characteristic curve 
C cytosine 
CI confidence interval 
CIN cervical intraepithelial neoplasia 
CIN2+ cervical intraepithelial neoplasia grade 2 or worse 
CIN3+ cervical intraepithelial neoplasia grade 3 or worse 
CpG site cytosine followed by guanine in DNA 
DNA deoxyribonucleic acid 
DS dual staining (p16, Ki67) 
dVIN differentiated vulvar intraepithelial neoplasia 
e.g. exempli gratia 
etc. et cetera 
G guanine 
HIV human immunodeficiency virus 
HPV  human papillomavirus 
hrHPV high-risk human papillomavirus 
HSIL high grade squamous intraepithelial lesion 
IARC International Agency for Research on Cancer 
i.e. id est 
ISRCTN International Standard Randomised Controlled Trial Number 
ITT intention-to-treat 
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Ki67 a cellular proliferation marker 
LCR long control region 
LEEP loop electrosurgical excision procedure 
LLETZ large loop excision of the transformation zone 
LSIL low grade squamous intraepithelial lesion 
mITT modified intention-to-treat 
NILM negative for intraepithelial lesion or malignancy 
NSAID nonsteroidal anti-inflammatory drug 
OR odds ratio 
PCR polymerase chain reaction 
pRB retinoblastoma protein 
p16 a cellular protein reflecting the activity of the HPV E7 oncogene 
p53 tumour protein 53 
RCI Reid colposcopic index 
RCT randomised controlled trial 
ROC curve receiver operating characteristic curve 
RR relative risk or risk ratio 
SCJ squamo-columnar junction 
STM specimen transport medium 
TBS the Bethesda system 
TZ transformation zone 
uVIN usual vulvar intraepithelial neoplasia 
VAIN vaginal intraepithelial neoplasia 
VIN vulvar intraepithelial neoplasia 
VLP virus-like particle 
WHO World Health Organisation 
5-FU 5-fluorouracil 
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1 INTRODUCTION  
Genital human papillomavirus (HPV) infections are extremely common, with nearly 
all humans having at least one infection during their lifetime (Bruni et al., 2010). First 
HPV infections are usually acquired right after sexual debut (Winer et al., 2003). The 
necessity of HPV in carcinogenesis in the uterine cervix is well established, but it 
alone is insufficient to cause cancer, because the majority of infections and even 
preinvasive lesions (intraepithelial neoplasias) resolve spontaneously (zur Hausen, 
1977; Ho et al., 1998; Walboomers et al., 1999; Castle et al., 2009). HPV is also 
recognised as a causative agent of neoplastic transformation in the vulva, vagina, 
anus, penis, and oropharynx (Forman et al., 2012). It has been estimated that, on 
average, it takes decades from an incident HPV infection to development of cervical 
cancer. Currently there is no way to predict the outcome of an individual HPV 
infection despite some well-established risk factors of carcinogenesis. 
 
Two major advances in HPV-related disease control have been made: cervical cancer 
screening and prophylactic vaccines. Organised nationwide screening programs 
based on cytology were started in developed countries such as Finland nearly 60 
years ago and have led to an 80% reduction in cervical cancer incidence and 
mortality, because preinvasive lesions can be treated (Laara, Day and Hakama, 1987). 
Globally, cervical cancer is still the fourth most prevalent cancer in women (Ferlay et 
al., 2018). High-risk HPV (hrHPV) testing has been established more recently as a 
more sensitive, albeit less specific, screening test expected to further reduce cancer 
rates in women attending screening (Koliopoulos et al., 2017). Prophylactic HPV 
vaccines have been available for a little over a decade. The prevalence of HPV 
infection and preinvasive disease has been tremendously reduced in countries with 
high vaccine coverage of adolescents (Kavanagh et al., 2017; Palmer et al., 2019). 
Evidence also exists of herd immunity, especially with gender-neutral vaccination 
(Lehtinen, Söderlund-Strand, et al., 2018a). 
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Unsolved issues remain despite these major advances. Local treatments of cervical 
preinvasive lesions are highly efficient in preventing cancer but can have important, 
long-term adverse effects, such as an increased risk of preterm birth or midtrimester 
miscarriage (Kyrgiou et al., 2017). The adverse effects and natural history estimates 
of cervical intraepithelial neoplasias, especially in young women, have led to the 
adoption of expectant management strategies where lesions are actively surveilled 
in hope of spontaneous resolution. A predictive test for outcomes could revolutionise 
management algorithms by allowing allocation of patients with risk of progression to 
cancer to immediate treatment and saving those with low risk from treatment-
related adverse effects. DNA methylation has shown promise in this area, because it 
has been shown to be able to predict which hrHPV infections lead to significant 
preinvasive disease (Lorincz et al., 2016).  
 
Treatment and detection of HPV-related disease at other sites than the cervix is more 
difficult. Vaginal disease is commonly revealed by cervical cancer screening, but 
treatment is complicated by anatomy and typical multifocal disease. Currently used 
treatments can also have serious long-term effects such as scarring, and recurrences 
are common in up to one third of patients, irrespective of treatment method 
(Gurumurthy and Cruickshank, 2012). Most current methods aim at excision or 
destruction of vaginal preinvasive lesions. A treatment targeting the causative agent, 
HPV, could potentially have better efficacy, because hrHPV persistence is a well-
recognised risk factor for recurrence. Imiquimod, an immune response modulator, 
has been found promising in small, non-randomised studies (Buck and Guth, 2003; 
Haidopoulos et al., 2005). 
 
Great promise lies in the prophylactic vaccines in eradication of HPV if coverage on 
the population level is sufficiently high, but evidence of long-term effectiveness 
against cancer is still awaited. In the meantime, it is still important to better our 
understanding of the process of HPV-related carcinogenesis and optimise 
treatments. This thesis aims to answer some aspects of these issues. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 HUMAN PAPILLOMAVIRUS INFECTION 
Human papillomavirus (HPV) is an icosahedral, non-enveloped, double-stranded, 
8000 base pair DNA virus belonging to the Papillomaviridae family. Papillomaviruses 
have been found to be both host-species-specific and tissue-specific, replicating in 
the basal layer of either cutaneous or mucosal surface epithelium. HPVs are divided 
based on DNA sequence analysis to five genera that are further divided into species. 
Over 200 HPV genotypes have been described, 40 of which are known to infect 
mucosal epithelium (Bzhalava, Eklund and Dillner, 2015). Thirteen of the mucosal 
HPVs are classified as group I or 2A carcinogens by the International Agency for 
Research on Cancer (IARC) and are commonly referred to as high-risk HPVs (hrHPV) 
(IARC, 2012). hrHPVs belong to various species of the alpha genera. Specific HPV 
genotypes (exempli gratia (e.g.) HPV16) have also been found to have different 
variant lineages and sublineages (Burk, Harari and Chen, 2013). A study on the 
geographical distribution of HPV16 lineages suggests that the ancestor of HPV16 was 
present in ancestral humans over 500 000 years ago (Pimenoff, de Oliveira and Bravo, 
2017). 
 
HPV is known to spread through direct epithelial contact and, most commonly, 
mucosal contact during sexual intercourse. A microtrauma is thought to be necessary 
for the virus to enter the basal cells of stratified epithelium, and the squamo-
columnar junction (SCJ) in the female cervix is especially vulnerable (Schiller, Day and 
Kines, 2010; Doorbar et al., 2012). Recent evidence exists that there are 
phenotypically distinct cells in the junctional area that are specifically targeted (Herfs 
et al., 2012).  
 
HPV relies on the host cells’ cellular machinery to complete its life cycle, and its 
genome remains a low copy number extrachromosomal episome in the nucleus of 
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the basal cell in early stage infections (Stubenrauch and Laimins, 1999; Pyeon et al., 
2009). HPV does not kill the host cell (Doorbar et al., 2012). The viral genome consists 
of a long control region (LCR) and early and late regions. Figure 1 shows a schematic 
representation of the HPV genome. These genes are expressed at different stages 
the host cell passes through in the proliferating and differentiating epithelium; the 
end result is assembled complete viral particles that are released from the surface of 
the epithelium (Fehrmann and Laimins, 2003). Early genes (for example E6, E7) are 
needed for viral replication and to promote host cell proliferation; late genes (L1, L2) 
code the viral capsid (Munger et al., 1989). Mucosal HPV infections are mostly 
asymptomatic apart from those causing visible genital warts. 
 
Figure 1 Schematic representation of the HPV genome. E6 inhibits tumour suppressor gene p53 and 
E7 retinoblastoma protein (pRB). L1 is the major capsid protein and L2 the minor capsid 
protein. 
 
HPV
genome
L1
L2
E4
E2
E1
E7
E6
E5
LCR
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2.1.1 NATURAL HISTORY OF HPV INFECTION 
Up to 90% of all HPV infections clear spontaneously within two years (Ho et al., 1998; 
Moscicki et al., 2006). Host immune response is generated when infected cells are 
shed from the surface of the epithelium and viral proteins are recognised by antigen 
presenting cells (APCs) and antibody producing B cells (Stanley, 2010a). APCs activate 
T cells, of which helper T cells enhance the antibody production of B cells, and 
cytotoxic T cells restrict the infection locally. A cell-mediated response to infection 
can be detected within weeks of infection, but a detectable antibody level occurs 
only after months (Stanley, 2006). HPV antibodies are thought to be genotype 
specific and, for an unknown reason, only approximately half of the infected 
individuals have a detectable humoral immune response (Mählck et al., 1999; Carter 
et al., 2000). Natural antibodies are likely to be protective against re-infection by the 
same genotype in approximately 50-70% of seropositive individuals (Lin et al., 2013; 
Beachler et al., 2016). 
 
The precise pathways leading to persisting infections are poorly understood. The 
longevity of the infected basal stem cell has been implicated (Egawa, 2003; Doorbar, 
2006). The infecting genotype clearly affects time to clearance, with HPV16 having 
the longest time to clearance (18-23 months), followed by 18, 31, 33, and 52 of the 
hrHPVs (Bulkmans et al., 2007). Different lineages of the same HPV genotype also 
appear to have different oncogenic potential (Schiffman et al., 2010). Low-risk HPV 
infections, however, usually clear within a few months (Stanley, 2010b). Infection 
with multiple HPV genotypes appears to have an increased risk of persistence; 
conversely, a co-infection with a low-risk genotype has been shown to promote 
clearance (Ho et al., 1998; Trottier et al., 2006; Sundström et al., 2015).  
 
Host cofactors associated with persistence and development of cervical neoplasia 
are mostly linked to a diminished immune response, such as immunosuppression 
(human immunodeficiency virus (HIV) infection, immunosuppressive medication), 
cigarette smoking, other sexually transmitted disease (Chlamydia trachomatis, 
Herpes simplex), and increasing age (Castellsague, Bosch and Munoz, 2002; Castle et 
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al., 2005; Castle et al., 2011). Younger women, in contrast, have usually the highest 
exposure to HPV because of behavioural factors leading to more persistent infections 
and cervical intraepithelial neoplasias (Wellings et al., 2006). Multiparity has also 
been implicated, but the mechanism is mostly thought to be indirect, and the 
increase was not as great in Finnish multiparous women as internationally reported, 
most likely because of lower incidence of other sexually transmitted infections 
(Hinkula et al., 2004). Oral contraceptive use has been implicated as a risk factor for 
persistence and neoplasia development, although findings are not consistent (Ylitalo 
et al., 1999; Giuliano et al., 2004; Adhikari et al., 2018). Persistence of an HPV 
infection is most likely multifactorial, including characteristics of both the virus and 
host. 
 
A clinical persistent infection can be thought to be present when the same hrHPV(s) 
is repeatedly detected (Moscicki et al., 2006). A clear sign of persistence can also be 
considered to be histopathological changes beyond signs of a productive HPV 
infection. Difficulty in defining persistence makes investigating the phenomenon also 
challenging. Differentiating between re-infection and a persistent infection is not 
always possible, and the onset of infection also cannot be reliably established, 
because it might have already persisted for any time period when first detected. The 
E6 and E7 viral genes become deregulated in persistent infections leading to cervical 
cancer precursors, and they may be integrated into the host genome, causing genetic 
instability and secondary somatic mutations leading to uncontrolled proliferation 
(Pett et al., 2004; Isaacson Wechsler et al., 2012). E6 and E7 are recognised as 
oncogenes inhibiting tumour suppressor genes (p53 and pRB) (de Sanjosé, Brotons 
and Pavón, 2018). The necessity of HPV infection in uterine cervical carcinogenesis 
has been well established, and this discovery was awarded the Nobel prize in 2008 
(zur Hausen, 1977; Walboomers et al., 1999). 
 
There is increasing evidence of latent HPV infections presenting with HPV DNA 
presence in basal cells even when the virus and histological changes are undetectable 
with current standard diagnostic methods (Gravitt, 2011; Maglennon, McIntosh and 
Review of the literature 
20 
Doorbar, 2011). A proportion of infections currently labelled as cleared might thus 
actually be latent. A latent infection is thought to be controlled by the host immune 
response, especially tissue resident T cells, but reactivation may occur if immune 
response is diminished (Doorbar et al., 2012; Gravitt, 2012). An example can be 
found, for example, in HIV-positive, sexually abstinent women in whom incident HPV 
detection progressively increases when CD4 cell counts decrease, i.e., immune 
response diminishes (Strickler et al., 2005). 
2.1.2 HPV EPIDEMIOLOGY 
Anogenital HPV infections are extremely common: at least 80% of humans become 
infected at least once during their lifetime, and 10% of humans have a prevalent HPV 
infection at any given time (de Sanjosé et al., 2007; WHO/ICO Information Centre on 
HPV and Cervical Cancer, 2007; Bruni et al., 2010). HPV prevalence increases steeply 
after sexual debut, with about half being infected within three years (Winer et al., 
2003; Kjaer et al., 2005). Risk factors for HPV acquisition are similar to those of HPV 
persistence and neoplasia development with the addition of number of lifetime 
sexual partners (Rositch et al., 2012). Many young women who have acquired a 
genital HPV infection will acquire another one, and behavioural factors, including also 
the number of sexual partners the current partner has had, appear to lead to this 
clustering of infections (Burk et al., 1996; Woodman et al., 2001; Muñoz et al., 2004; 
Vaccarella et al., 2006; Trottier et al., 2010). 
 
Overall HPV prevalence is highest, at up to nearly 50%, in young women under the 
age of 25 and decreases thereafter until a second but smaller peak is sometimes seen 
in peri- and postmenopausal women (Castle et al., 2005; Franceschi et al., 2006; 
Schiffman et al., 2010). The HPV point prevalence was found to be 33% in Finnish 
female first-year university students (Auvinen et al., 2005). Age-specific prevalence 
curves, however, vary greatly geographically and according to income in populations 
(Franceschi et al., 2006).  The reason for the second prevalence peak remains under 
debate, because behavioural factors (such as new sexual partners) appear to be 
 21 
insufficient to explain it (Bosch et al., 2008). Reactivated latent infections after 
immune senescence have been proposed as a possible explanation. A second peak, 
however, is not seen universally in all studies (Schiffman, 1992; Franceschi et al., 
2006). A study from the USA reported hrHPV prevalence in a cervical cancer 
screening population to be 17.8% in 25-29-year-olds, but only 6.5% in women over 
50 years of age, and 3.5% and 0.8%, were HPV16 positive in those groups, 
respectively (Monsonego et al., 2015). Similar findings on age trends have been 
reported also from the UK and Finland (Sargent et al., 2008; Leinonen et al., 2013).  
 
Globally, HPV point prevalence in general varies greatly from 20-30% in Africa and 
South America to 6-7% in Southeast Asia and Southern Europe (Clifford et al., 2005; 
de Sanjosé et al., 2007). A study in the 1990s found the hrHPV prevalence to be 7% 
in Finnish women of screening age (Syrjanen et al., 1992). Genotype-specific 
prevalence shows distinct geographical patterns, but HPV16 is globally the most 
prevalent genotype, followed by HPV18 (Bruni et al., 2010). Table 1 presents the 
estimated genotype-specific prevalence in women with normal cytology worldwide, 
in Europe, in a screening population in Sweden, and in an hrHPV test-positive 
screening population in Finland. In the Finnish study, 7.8% of the overall population 
tested hrHPV positive, but 30% of hrHPV test-positive women were found to be HPV 
negative in genotyping, which may have affected the overall prevalence results 
(Leinonen, 2013; Leinonen et al., 2013). The reason for this is unclear, but genotyping 
was performed much later than the hrHPV test, which was directly analysed. When 
compared to overall European data, HPV16 and HPV18 are less prevalent, and HPV52 
is more prevalent in Finland (de Sanjosé et al., 2007; Bruni et al., 2010). HPV52 was 
also found to be more prevalent than the European average in Denmark (Kjaer et al., 
2008). 
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Table 1. Point prevalence of HPV genotypes in different geographical regions in women with 
normal cytology and in screening populations in Sweden and Finland. 
 
2.2 PROPHYLACTIC HPV VACCINES 
Vaccines have been developed for the primary prevention of HPV infection. 
Prophylactic HPV vaccines contain virus-like particles (VLP) that mimic the viral capsid 
protein encoded in the L1 region of the viral genome of specific HPV genotypes 
(Schiller and Lowy, 2001). Three prophylactic vaccines have been or are commercially 
available. The bivalent vaccine targets HPV16 and 18, the quadrivalent vaccine 
targets the former two and HPV6 and 11 that commonly cause genital warts, and the 
9-valent vaccine targets all the formerly mentioned and HPV31, 33, 45, 52, and 58 
(FUTURE II Study Group, 2007; Paavonen et al., 2007; Joura et al., 2015). The 
quadrivalent vaccine has recently been replaced by the 9-valent vaccine. 
 
Many developed countries and some developing countries have included the HPV 
vaccine in their national vaccination program. Most programs still include only 
vaccination of adolescent girls, such as the Finnish program that started in 2013, but 
some countries have moved to vaccinating gender neutrally, which results in better 
herd immunity (Lehtinen, Luostarinen, et al., 2018; Lehtinen, Söderlund-Strand, et 
al., 2018b). The National Institute for Health and Welfare recommended 
Genotype
Worldwide 
Bruni et al. 2010 
n=215 568
Europe
Bruni et al. 2010
n=129 646
Sweden
Forslund et al. 2002
n=6123
Finland
Leinonen thesis 2013
n=33 043
HPV16 3.2% 4.8% 2.1% 0.9%
HPV18 1.4% 0.9% 0.6% 0.4%
HPV31 0.8% 2.3% 1.1% 0.7%
HPV33 0.5% 0.6% 0.4% 0.3%
HPV52 0.9% 0.4% 0.3% 0.5%
HPV58 0.7% 0.4% 0.3% 0.4%
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commencing gender-neutral HPV vaccination in Finland in January 2019  (The 
National Institute for Health and Welfare recommends including the HPV vaccine in 
the boys’ vaccination programme - Press release - THL, 2019). Current trends of fear 
of vaccine-related adverse events in the general public, among other factors, have 
affected uptake of the HPV vaccines (Ferrer et al., 2014). Several studies, however, 
have shown no difference in long-term adverse events or adverse pregnancy 
outcomes in HPV-vaccinated and unvaccinated populations (Arnheim-Dahlstrom et 
al., 2013; Lehtinen et al., 2016; Arbyn et al., 2018; Skufca et al., 2018). 
2.2.1 IMMUNOGENICITY  
The magnitude of antibody response to the vaccines is vastly greater than that of a 
natural infection and has been demonstrated in all vaccinated subjects, in contrast 
to the lack of natural antibodies in many individuals after natural infection (FUTURE 
II Study Group, 2007; Paavonen et al., 2007; Joura et al., 2015). Vaccines are 
commonly administered as a two-dose regimen within 6 months. A three-dose 
regimen is recommended after adolescence or in immunocompromised individuals. 
Antibody levels are up to 100-fold higher after vaccination than after natural 
infection and remain elevated in the case of the bivalent vaccine for nearly a decade, 
but some waning has been shown for antibody levels with the quadrivalent vaccine 
(Villa et al., 2006; Roteli-Martins et al., 2012; Artemchuk et al., 2018). Protection 
against infection and cervical neoplasias appears to remain high despite lowering 
serum antibody levels (Joura et al., 2008; Einstein et al., 2009). Immunogenicity of 
the vaccines has been demonstrated to be age-specific with a better response in 
children and adolescents  under age 15 (Pedersen et al., 2007; Perez et al., 2008). 
2.2.2 EFFICACY 
The prophylactic vaccines have been shown to be highly efficacious against HPV 
infection and cervical intraepithelial neoplasia (CIN) in phase III trials. There is also 
evidence of cross-protection towards high-risk genotypes not targeted by the 
vaccines in the case of the bivalent and quadrivalent vaccine (Brown et al., 2009; 
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Wheeler et al., 2012; Woestenberg et al., 2018). Table 2 (Villa et al., 2006; Lehtinen 
et al., 2012; Joura et al., 2015) and 3 (Munoz et al., 2010; Lehtinen et al., 2012; Joura 
et al., 2015; Huh et al., 2017) show efficacy estimates of the prophylactic vaccines. 
The trials consisted of adolescents and young women (under 26 years of age) with 
follow-up up to approximately five years. The vaccines were found to be more 
efficacious in HPV-naïve women in comparison to individuals already harbouring HPV 
infection. 
Table 2. Vaccine efficacy against genotype-specific HPV infection in HPV-naïve subjects (%, 95% 
confidence interval (CI)). 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome Bivalent Quadrivalent 9-valent*
HPV16 94.7 (91.8-96.7) 91.6 (73.3-98.4) -
HPV18 92.3 (86.5-96.0) 91.6 (43.3-99.8) -
HPV31 77.1 (67.2-84.4) 46.2 (15.4-66.4) 95.5 (90.7-97.9)
HPV33 43.1 (19.3-60.2) 28.7 (-45.1-65.8) 99.1 (95.2-100)
HPV45 79.0 (61.3-89.4) 7.8 (-67.0-49.3) 96.8 (92.1-98.9)
HPV52 18.9 (3.2-32.2) 18.4 (-20.6-45.0) 97.3 (95.3-98.7)
HPV58 -6.2 (-44.0-21.6) 5.5 (-54.3-42.2) 94.8 (91.0-97.1)
* 9-valent vaccine compared against the quadrivalent and found non-inferior 
in protection against HPV16/18
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Table 3. Vaccine efficacy against CIN grade 2 or worse (CIN2+) in HPV-naïve subjects and in 
intention-to-treat (ITT) populations (%, 95% CI) 
 
The quadrivalent vaccine also shows high efficacy against genital warts: 97.1% (95% 
confidence interval (CI) 92.4-99.2%) in HPV-naïve women and 79.3% (95% CI 72.7-
84.5%) in baseline HPV-positive women (FUTURE I/II Study Group, 2010). Efficacy of 
the quadrivalent vaccine against high-grade vaginal and vulvar intraepithelial 
neoplasia (VAIN/VIN2-3) irrespective of HPV genotype is also high: 77.1% (95% CI 
47.1-91.5) in HPV-naïve women and 50.7% (95% CI 22.5-69.3) in baseline HPV-
positive women (Munoz et al., 2010). 
 
A recent Cochrane review of prophylactic HPV vaccines includes 26 trials with over 
70 000 participants with follow-up from 1.3 to 8 years (Arbyn et al., 2018). The review 
concluded that there is high certainty evidence of vaccine protection against high-
grade cervical lesions in young (15-26-year-old) women, and the effect is greatest 
against disease associated with HPV16/18 and in those who are hrHPV negative at 
time of vaccination. In older women there was moderate certainty evidence that 
vaccination reduces high-grade cervical disease in HPV16/18-negative women but 
not if they are unselected by hrHPV status. All of this emphasises the importance of 
vaccination in adolescence before exposure to HPV. 
Outcome
Bivalent Quadrivalent 9-valent*
naïve ITT naïve ITT naïve mITT
CIN2+
(HPV16/18+)
99.0
(94.2-100.0)
60.7
(49.6-69.5)
100.0
(91.4-100.0)
53.0
(38.2-64.5)
- -
CIN2+
(HPV16/18-)
64.9
(52.7-74.2)
33.1
(22.2-42.6)
42.7
(23.7-57.3)
19.3
(5.7-31.0)
97.4
(85.0-99.9)
71.4
(40.8-86.2)
* 9-valent vaccine compared against the quadrivalent and found non-inferior in protection against 
HPV16/18+ CIN2+; CIN2+ in the modified ITT (mITT) includes also high-grade vaginal and vulvar disease
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2.2.3 EFFECTIVENESS 
The first national HPV vaccination programs started a little over a decade ago. 
Reports from the past five years from Scotland and Australia show significant real-
life reductions in hrHPV infections in women vaccinated in adolescence (Kavanagh et 
al., 2014, 2017; Tabrizi et al., 2014; Cameron et al., 2016; Machalek et al., 2018; 
Garland et al., 2018). A study from Scotland with over 8 000 participants showed a 
vaccine effectiveness of 89.1% (95% CI 85.1-92.3) against HPV16/18 in adolescent 
females vaccinated at 12-13 years of age with the bivalent vaccine (Kavanagh et al., 
2017). A cross-protective effect was seen with close to or over 80% effectiveness 
regarding HPV31/33/45 infections; the risk of infection by vaccine-related genotypes 
was also reduced in the unvaccinated population, implying herd immunity. Australian 
studies on the quadrivalent vaccine effectiveness showed similar reductions in 
HPV16/18 and evidence of herd immunity, but of less cross-protection (Tabrizi et al., 
2014; Garland et al., 2018). Effectiveness data on the 9-valent vaccine is still awaited, 
as it has been available for a shorter period of time.  
 
Significant reductions of CIN after national vaccination program implementation of 
the HPV vaccine in Scotland, Australia, and five regions in the USA have been shown 
in a few studies, but long-term results are awaited, because vaccinated women are 
only starting cervical cancer screening (Crowe et al., 2014; Pollock et al., 2014; Hariri 
et al., 2015; Cameron et al., 2017; Palmer et al., 2019). The most recent study from 
Scotland of over 100 000 young women showed a nearly 90% reduction of high-grade 
CIN (Palmer et al., 2019). Two registry-based studies from the Nordic countries found 
vaccine effectiveness against CIN3 or worse (CIN3+) to be 66-90% a decade after 
vaccination (Lehtinen et al., 2017; Kjaer et al., 2018). First proof of protection against 
invasive cancer from a randomised setting has also been reported (Luostarinen et al., 
2018). 
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2.3 HPV-RELATED NEOPLASIAS OF THE FEMALE GENITAL TRACT 
2.3.1 CERVICAL INTRAEPITHELIAL NEOPLASIA 
2.3.1.1 Classification 
The ectocervix is covered with stratified squamous epithelium and the endocervix 
with columnar (glandular) epithelium, although the location of the SCJ and 
surrounding transformation zone (TZ) differs according to age and hormonal status. 
Histopathological grading of preinvasive squamous disease of the uterine cervix, CIN, 
was first described by Richart in 1973 (Richart, 1973). He divided CIN into three 
grades based on the thickness of the abnormal cells in the squamous epithelium: CIN 
grade 1 (CIN1) remaining only in the basal layer, CIN grade 2 (CIN2) up to half of the 
thickness of the epithelium, and CIN grade 3 (CIN3) the full thickness of the 
epithelium. Invasive cervical cancer is characterised by the breach of the basal layer 
by the neoplastic cells and the possibility of metastatic disease. 
 
This three-tier classification is known to suffer from great histopathological intra- and 
interobserver variability which, in conjunction with natural history estimates of 
different CIN grades, has led to a revised classification by the World Health 
Organisation (WHO) in 2014 (Ismail et al., 1989; Stoler and Schiffman, 2001; WHO, 
2003, 2014). CIN2 and 3 (dysplasia moderata, dysplasia gravis) are grouped together 
in the new histopathological classification as high-grade squamous intraepithelial 
lesion (HSIL), and CIN1 (dysplasia levis) and former HPV atypia/atypia condylomatosa 
et cetera (etc.) are replaced by low-grade squamous intraepithelial lesion (LSIL). LSIL 
is currently considered a sign of a productive HPV infection and not a true cancer 
precursor (Wright, 2006). Figure 2 shows a schematic representation of histological 
changes in cervical neoplastic disease and CIN classifications and possible relations 
to HPV infection. 
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Figure 2 Schematic figure of histological changes in different CIN grades and carcinoma, different 
CIN gradings, and association with HPV infection 
 
Classification of glandular lesions is more difficult and has been greatly revised 
throughout time. The new 2014 classification promotes the use of adenocarcinoma 
in situ (AIS) to describe a preinvasive glandular disease without any other precursors 
(WHO, 2014). AIS is recognised as a precursor to adenocarcinoma of the cervix 
(Sheets, 2002; Zaino, 2002). 
2.3.1.2 CIN epidemiology and natural history 
CIN is more common in young women, with a peak prevalence in the late 20s and 
early 30s that reflects the earlier peak of HPV infections after sexual debut (Finnish 
Cancer Registry, no date). Some HPV16 or 18 infections, however, appear to be more 
aggressive with even CIN3 developing in only a few years after infection (Winer et 
al., 2005). Despite this, only a small proportion of HPV infections lead to CIN, and 
known risk factors are similar to those of persistent HPV infection. CIN in peri- and 
postmenopausal women is rare, at least in developed countries with efficient 
screening programs and adequate registries. However, cervical cancer incidence 
peaks at around 35-40 years of age (median age 45) in these countries, and remains 
Normal
No HPV Transient HPV
Persistent HPV
Productive
infection
Intraepithelial
neoplasia
Invasive cancer
Epithelium
WHO 2014
WHO 2003 HPV atypia etc. CIN1 CIN2 CIN3 Microinvasive
carcinoma
Carcinoma
LSIL HSIL Carcinoma
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elevated in older women, when mortality also increases (Engholm et al., no date; 
Finnish Cancer Registry, no date; Hallowell et al., 2018). 
  
As with HPV infections, spontaneous regression of CIN also occurs commonly. There 
is a higher tendency for spontaneous resolution when the CIN grade is lower. Table 
4 provides a summary of some studies examining the natural history of different CIN 
grades. Even though estimates differ, possibly due to differences in study design and 
population, CIN1/LSIL regresses often spontaneously with progression to high-grade 
disease in approximately 10%. 
 
Table 4. Natural history estimates of different CIN grades 
 
  
 
Estimates for CIN2 are varying, and many studies, especially in the last decade, have 
shown high regression rates in young women (Fuchs et al., 2007; Moore et al., 2007; 
Monteiro et al., 2010; Moscicki et al., 2010; McAllum et al., 2011; Loopik et al., 2016). 
However, a recent retrospective analysis of more than 2000 women with untreated 
Author 
(year)
CIN1/LSIL CIN2 CIN3
Regr
%
Persis
%
Progr
%
Regr
%
Persis
%
Progr
%
Regr
%
Persis
%
Progr
%
Östör (1993) 1 57 32 11 (1) 43 35 22 (5) 32 56 12
Holowaty et al. (1999) 2 44 - 11 33 - 16 - - -
Cox et al. (2003) - - 9 - - - - - -
Elit et al. (2011) - 5 4 - - - - - -
Gurumurthy et al. (2014) - - 12 - - - - - -
Nasiell et al.(1983) - - - 54 16 30 - - -
Moscicki et al. (2010) 3 - - - 63 17 12 - - -
Castle et al. (2009) - - - 40 - - - - -
McCredie et al. (2008) 4 - - - - - - - - 17 (34)
1 Progression to invasion in parentheses; 2 Rates within 2 years; 3 Progression and regression rates at 2 
years, persistence at 3 years; 4 Progression to invasion at 5 years and at 20 years in parentheses
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CIN2 (including CIN1/2 and CIN2/3) between the ages of 21 and 39 showed that only 
a fifth of them were able to return to routine screening after a median follow-up of 
48 months (Silver et al., 2018). Nearly half remained under colposcopic surveillance 
for low-grade lesions or persisting hrHPV. The study reported six cases (0.2%) of 
invasive cancer, half of which were characterised by failure to return for surveillance, 
and none occurred after negative cytology and hrHPV test. 
 
Natural history estimates on CIN3 are historic, because those studies would now be 
considered mostly unethical. A review by Östör and a study from New Zealand show 
marked progression to invasive cancer, albeit regression or at least non-progression 
appears to happen also (Östör, 1993; McCredie et al., 2008, 2010). As not all CIN3 
lead to invasive cancer, characteristics of CIN3 cases have been evaluated, and 
greater lesion size was seen with advancing age, while HPV16-related CIN3 was 
diagnosed at a younger age (Schiffman and Rodríguez, 2008; Yang et al., 2012; 
Wentzensen et al., 2013). The natural history of glandular abnormalities is not well-
described, because diagnostics are more difficult than in the case of squamous 
neoplasias (Krivak et al., 2001; Ruba et al., 2004). AIS is diagnosed simultaneously 
with high-grade squamous neoplasia in 50% of cases, and it has been estimated that 
the disease is multifocal in over 10% of cases (Östör et al., 2000; Zaino, 2002). 
 
2.3.1.3 HPV genotype distribution in CIN and cancer 
 
HPV genotype distribution differs in different CIN grades. The proportion of 
HPV16/18-related CIN increases with increasing severity of findings. HPV16 was 
found in approximately 28% of CIN1, 40% of CIN2, and 58% of CIN3 in a meta-analysis 
of studies that included approximately 20 000 cases of CIN worldwide (Guan et al., 
2012). HPV18, in contrast, was found in approximately 10% of CIN irrespective of 
grade, with a steeper increase to 16% in invasive cancers. The proportion of HPV16 
in cervical cancer in this study was estimated to be 63%. In studies on genotype 
distribution in cervical cancer, approximately 70% are associated with HPV16/18 
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(Wheeler et al., 2009; de Sanjose et al., 2010). A recent large population-based study 
from Sweden found 19% of invasive cervical cancers to be HPV negative, while only 
3% of CIN3 were negative using genotyping for detection (Hortlund et al., 2016; Lei 
et al., 2018). Most likely most of the cancer cases were originally hrHPV positive, but 
with HPV negativity associated with advanced stage disease and older age at 
diagnosis, HPV might have become undetectable when the carcinogenic process 
proceeds. More rare HPV-negative cervical cancers also exist, primarily 
adenocarcinomas (McCluggage, 2016). 
 
Other genotypes dominating in higher grade disease and cancer are HPV45, 52, 31, 
33, and 58: approximately 4-11% of cases are attributed to these individual 
genotypes (Guan et al., 2012). HPV16-related high-grade cervical changes have been 
found to be more common at a younger age in some studies (Porras et al., 2009; 
Wheeler et al., 2009; Castle et al., 2010; Castle, Shaber, et al., 2011). Also, up to 25% 
of histological LSIL is attributed to HPV16; conversely, some studies report 24-45% of 
LSIL to be associated with other than hrHPV genotypes (Cavalcanti et al., 2000; 
Silveira et al., 2015). In a Finnish study on cytological LSIL, over two-thirds were 
positive for hrHPV, and CIN2 or worse (CIN2+) was found in nearly 15% (Veijalainen 
et al., 2015). HPV18 and 45 have been found to be more common in glandular disease 
in comparison to squamous disease (Clifford and Franceschi, 2008; Wheeler et al., 
2009; Castle, Shaber, et al., 2011). Some HPV16 sublineages have been shown to be 
overrepresented in glandular disease, especially (Mirabello et al., 2016). 
2.3.1.4 CIN diagnostics 
HPV infection and CIN are mostly asymptomatic; thus, the primary diagnostic 
approach for decades has been microscopy of exfoliated cervical and vaginal cells 
(cytology). Cervical cytology testing was first described by Georgios Papanicolau in 
the 1920s (Papanicolaou, 1928; Papanicolaou and Traut, 1941). The traditional 
method, in which three individually scraped samples are taken from the vaginal 
fornices, ectocervix, and endocervix and placed on a glass slide, is still called a 
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Pap(anicolau) smear. Liquid-based cytology, where exfoliated cells are collected with 
a brush or spatula and rinsed into a preservative solution, was developed in the 
1990s in an attempt to reduce the false negative rate of conventional cytological 
samples (Lee et al., 1997).  
 
Cervical cancer is globally the fourth most common cancer in women, with an 
annual incidence of over half a million cases and over a quarter million annual 
deaths (Ferlay et al., 2018). Cervical cancer is also an exceptional cancer, because 
precancerous lesions can be detected and treated with great cost effectiveness. 
These features make mass screening for cervical cancer justified according to WHO 
criteria (Wilson and Jungner, 1968). Organised cervical cancer screening with 
cytology has dramatically decreased cervical cancer incidence and mortality in 
many countries (Arbyn et al., 2009). The nationwide organised screening program 
started in Finland in the 1960s has led to an 80% reduction in cervical cancer 
incidence and mortality (Laara, Day and Hakama, 1987; Nieminen, Kallio and 
Hakama, 1995; Hristova and Hakama, 1997; Anttila et al., 1999). Hence, the 
majority of cervical cancer burden today remains in countries with low resources 
for screening and treatment. Finnish municipalities are obligated by legislation to 
organise cervical cancer mass screening for women between the ages of 30 and 60 
at 5-year intervals. 
 
Classification of cervical cytological findings has been revised throughout time, and 
the current recommendation is the Bethesda system (TBS) updated in 2001 (Table 
5), which emphasises also the adequacy assessment of the sample (Solomon et al., 
2002). Cytological findings are considered an insufficient basis for diagnosing cervical 
disease; the preferred method is histology obtained by colposcopically directed 
biopsies. Cytology is used to screen for cervical abnormalities and, depending on 
local guidelines, different cut points are used for referral to further examinations. 
Possible symptoms of HPV infection and CIN include irregular or postcoital bleeding 
(Gulumser et al., 2015). Women presenting with these symptoms should have 
cytological testing and be referred to colposcopy if a reason for abnormal bleeding 
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cannot be otherwise identified (Abu, Davies and Ireland, 2006; Cytological 
abnormalities: Finnish Current Care Guidelines (online)., 2019).  
 
Table 5. Overview of cervical cytology categories according to the Bethesda system (TBS 2001) 
 
 
The accuracy of cytology, especially sensitivity, in finding high-grade cervical disease 
is highly varying. One meta-analysis found the sensitivity to be 30-87% with 
specificity of 86-100% (Nanda et al., 2000). A study of over 60 000 women in Europe 
and North America found the sensitivity of cytology to be 53% and specificity 96% 
Normal findings
NILM
negative for intraepithelial lesion or 
malignancy
Abnormal findings
Squamous Glandular
ASC-US
atypical squamous 
cells of undetermined 
significance
AGC-NOS
atypical glandular 
cells not otherwise 
specified
LSIL
low grade squamous 
intraepithelial lesion
ASC-H
atypical squamous 
cells, cannot rule out 
HSIL
AGC-FN
atypical glandular 
cells favour neoplasia
HSIL
high grade squamous 
intraepithelial lesion
Squamous cell 
carcinoma
squamous cell 
carcinoma
Adenocarcinoma adenocarcinoma
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(Cuzick et al., 2006). Variability of estimated sensitivity can be attributed to the 
quality of the health care system, including sampling and interpretation of samples. 
In Finland sensitivity of conventional cytology in detecting CIN2+ has been reported 
to be up to 83% with a specificity of 94% when the cut point for cytology was set at 
LSIL or worse, and also the false-negative rate has been found to be low (Nieminen 
et al., 2004; Lonnberg et al., 2010). Sensitivity of cytology is especially poor in 
glandular abnormalities, and AIS has been found to have false-negative cytology in 
up to 50% (Nieminen, Kallio and Hakama, 1995; Ruba et al., 2004; Sasieni, Castanon 
and Cuzick, 2009).  
 
High-grade cervical disease is associated with persistent hrHPV infection; thus, hrHPV 
testing has been introduced for primary screening. Many large, randomised studies 
from different countries have shown hrHPV testing to have higher sensitivity, albeit 
less specificity, when compared to cytology in detecting high-grade cervical disease 
(Naucler et al., 2007, 2009; Kitchener et al., 2009; Ronco et al., 2010; Castle, Stoler, 
et al., 2011; Leinonen et al., 2012; Rijkaart et al., 2012). A recent Cochrane review of 
over 140 000 women in 40 studies reached the same conclusion (Koliopoulos et al., 
2017). A negative hrHPV test has a longer disease-free period even for cervical cancer 
when compared to negative cytology, making longer screening intervals possible and 
sensible, because transient infections would most likely subside in between 
screening rounds (Ronco et al., 2014). The lower specificity of hrHPV testing, 
however, can lead to more referrals to colposcopy, because not all women 
harbouring an hrHPV infection present with any histological abnormalities or, 
moreover, abnormalities requiring treatment. It has been estimated that only 
approximately a third of women with a detectable single hrHPV infection present 
with cytological or histopathological abnormalities (Kovacic et al., 2006). Most 
municipalities in Finland currently offer cytology-based screening, but there is an 
ongoing shift towards hrHPV screening with cytology triage (Veijalainen et al., 2016, 
2019). 
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Colposcopy is performed when cervical disease is suspected, usually based on 
cytological abnormalities. Urgency of colposcopy depends on clinical, cytological, 
and/or hrHPV test findings. Table 6 shows the timing of colposcopy according to 
cytology in the Finnish Current Care Guidelines (Cytological abnormalities: Finnish 
Current Care Guidelines (online), 2019). A colposcope is a binocular microscope 
allowing magnification up to 40-fold (Anderson et al., 1996). Topically applied acetic 
acid (3-5%) is used, causing coagulation of superficial intracellular proteins that 
results in whitening of the epithelium (acetowhitening) (Anderson et al., 1996). 
Iodine can be used as an adjunct to acetic acid. This can be especially helpful for 
detection of vaginal lesions (Sopracordevole et al., 2018). 
Table 6. Overview of recommendations for colposcopy timing by cytological finding according to 
Finnish Current Care Guidelines 
 
 
Reason for Colposcopy Timing
Carcinoma Immediately (within 1-7 days)
HSIL, ASC-H, AGC-FN Within 1 month
LSIL According to cytopathologist’s
recommendation1
ASC-US 
(repeated 2-3 times within 12-24 months or 
in over 30-year-olds concomitant hrHPV
positivity)
Within 6 months
AGC-NOS Within 2 months or according to 
cytopathologist’s recommendation2
Abnormal endometrial cells Within 1 month
1 ≥30-year-olds within 6 months; <30-year-olds within 6 months if cytopathologist
recommends colposcopy OR if a repeated smear within 6-12 months is abnormal after which 
colposcopy within 6 months (if repeat cytology is also ≤LSIL)
2 within 2 months if cytopathologist recommends colposcopy OR if a repeated smear within 
4-6 months is abnormal
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Detected acetowhite or iodine-negative areas are further magnified and examined 
to see if changes suggestive of CIN are seen. In CIN the angioarchitecture 
subepithelially changes, resulting in mosaic-like surface structure, punctuation, and 
frank abnormal vessels. Acetowhitening, however, occurs also in metaplastic or 
regenerative epithelium, which makes colposcopic diagnosis challenging. Special 
attention should be paid to the most vulnerable area in the cervix, the TZ and SCJ. 
The location of the SCJ may vary and is not always visible, so the accuracy of 
colposcopy suffers. Scoring systems such as the Reid colposcopic index (RCI) and the 
Swede score have been developed to improve accuracy of colposcopic examination 
(Reid and Scalzi, 1985; Strander et al., 2005). 
 
The gold standard for diagnosis of CIN that should guide treatment decisions is 
colposcopically directed punch biopsies taken from the most abnormal areas seen in 
colposcopy (American College of Obstetricians and Gynecologists, 2008). Taking 
multiple biopsies has been shown to increase diagnostic accuracy, because 
colposcopy alone may lack in sensitivity (Massad and Collins, 2003; Gage et al., 2006; 
Jeronimo and Schiffman, 2006). A meta-analysis of the accuracy of punch biopsies in 
diagnosing high grade cervical disease found the sensitivity in detecting CIN2 or 
worse (CIN2+) to be over 90% and the specificity to be approximately 25% 
(Underwood et al., 2012). The authors point out, however, that the analysis included 
only women with positive punch biopsies, which may have resulted in bias, increasing 
sensitivity and lowering specificity. 
2.3.1.5 CIN treatment 
CIN is treated with local excisional and ablative surgical techniques. Nonsurgical 
methods have also been studied but are not currently used in clinical practice (de Vet 
et al., 1991; Alvarez et al., 2003; Grimm et al., 2012; Rahangdale et al., 2014).  
 
Of the excisional techniques, cold knife conisation in an operating room under 
general anaesthesia was traditionally performed. Since the 1990s this has been 
replaced to a great extent with large loop excision of the transformation zone 
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(LLETZ), also known as loop electrosurgical excision procedure (LEEP) in an outpatient 
setting with local anaesthesia, but practices vary greatly by country (Prendiville, 
Cullimore and Norman, 1989; Petry et al., 2008). Laser excision with carbon dioxide 
laser or needle excision may also be used. All of these excisional procedures aim at 
complete excision of the TZ, including the lesion. Excisional techniques provide a 
cone-shaped histological specimen that can be used to affirm the initial histological 
diagnosis and complete removal of the lesion.  
 
Ablative techniques include laser vaporisation, cryotherapy, and radical diathermy 
that aim to destroy the lesion with margins. Ablative treatment should be restricted 
to patients with fully satisfactory colposcopy (fully visible transformation zone), no 
suspicion of invasion or glandular disease, and no discrepancy in cytological and 
histological diagnosis (Jordan et al., 2009; Martin-Hirsch et al., 2013). No local 
treatment method has been found to be superior with regard to treatment failure or 
associated morbidity (Martin-Hirsch et al., 2013). All local treatments should be 
performed under colposcopic control (Cytological abnormalities: Finnish Current 
Care Guidelines (online)., 2019). Hysterectomy can be considered in cases of 
(repeated) local treatment failure (Cytological abnormalities: Finnish Current Care 
Guidelines (online)., 2019). 
 
Finnish Current Care Guidelines discourage routine direct local treatment based on 
cytology and colposcopic appearance alone (see-and-treat). Exceptions to this are 
AGC-FN cytology, since the endocervical canal cannot be fully visualised; HSIL 
cytology when the colposcopic appearance is also that of high-grade disease; and 
HSIL and ASC-H cytology if the SCJ is not visible in colposcopy (select-and-treat) 
(Cytological abnormalities: Finnish Current Care Guidelines (online)., 2019). 
 
The threshold to treat CIN has varied throughout time. Most treatment guidelines 
now suggest active surveillance for LSIL for up to two years, since it is considered a 
sign of a productive HPV infection with frequent spontaneous regression and low risk 
of progression (TOMBOLA Group, 2009; Massad et al., 2013; Cytological 
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abnormalities: Finnish Current Care Guidelines (online)., 2019). A finding of CIN2+ is 
mostly considered the cut-off to proceed to treatment. Currently some treatment 
guidelines suggest active surveillance also for CIN2 in young women, because 
spontaneous regression rates are recognised to be higher (Massad et al., 2013; 
Cytological abnormalities: Finnish Current Care Guidelines (online)., 2019). AIS should 
always be treated, and hysterectomy is recommended, but local excisional treatment 
can be considered in women who have not completed child bearing (Cytological 
abnormalities: Finnish Current Care Guidelines (online)., 2019). 
 
Complications of local treatment include short-term and long-term ones. Short-term 
complications include pain, haemorrhage, discharge, and infection. Haemorrhage 
can occur during treatment or, secondarily, afterwards. Two studies have reported 
delayed bleeding after outpatient LLETZ in approximately 1-5% of patients, of whom 
over a fourth to a half required additional haemostatic procedures or hospital 
admission (Dunn, Killoran and Wolf, 2004; Mossa et al., 2005). Self-reported 
moderate-to-severe bleeding or discharge occurs, however, in approximately 50% of 
women after LLETZ (Sharp et al., 2009). Infection after LLETZ has been reported in 1-
14% of cases, while it can be up to over a third after cold knife conisation 
(Kietpeerakool et al., 2017).  
 
Long-term complications include stenosis of the cervical canal and preterm birth or 
midtrimester miscarriage. Cervical stenosis prevents menstrual blood from exiting 
the uterus and can be thought to affect fertility by preventing sperm from entering 
the uterine cavity (Baldauf et al., 1996). It also disturbs future cervical diagnostic 
procedures. Risk of cervical stenosis has been associated with increasing cone depth, 
but the risk is still quite low in general (Baldauf et al., 1996; Mossa et al., 2005). Local 
treatment of CIN increases the overall risk of preterm birth (<37 weeks of gestation) 
from 5.4% to 10.7% (relative risk (RR) 1.78, 95% CI 1.60-1.98) and the risk of 
extremely premature birth (<28-30 weeks of gestation) from 0.3% to 1.0% (RR 2.54, 
95% CI 1.77-3.63) in a recent meta-analysis (Kyrgiou et al., 2016). This risk has been 
found to be associated with treatment method, cone depth, and number of 
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treatments with cold knife conisation and repeated treatments causing the most risk 
and ablative techniques the least risk (Kyrgiou et al., 2017). Women with previous 
CIN even without treatment were also found to have a slightly increased risk of 
premature birth when compared to women without a history of CIN (Kyrgiou et al., 
2016). Treatment of CIN has not been associated with reduced fertility (Kyrgiou et 
al., 2015). 
 
Women treated for CIN are known to have increased risk for CIN or cervical or vaginal 
cancer for up to or over twenty years after treatment (Soutter et al., 1997; Kalliala et 
al., 2005; Strander et al., 2007; Rebolj et al., 2012; Strander, Hällgren and Sparén, 
2014). Local treatments, however, are highly effective with an initial success rate of 
over 90% (Martin-Hirsch et al., 2013). Most recurrent cases occur within two years 
of treatment and a recurrence rate of 4-18% has been reported (Arbyn, Ronco, et al., 
2012). Risk factors for recurrent disease are positive excision margins (more so if the 
endocervical margin is positive versus the ectocervical), persistence of hrHPV, and 
older age at treatment (Flannelly et al., 2001; Verguts et al., 2006; Ghaem-Maghami 
et al., 2007; Serati et al., 2012; Strander, Hällgren and Sparén, 2014; Arbyn et al., 
2017). hrHPV positivity after treatment was found to be a more accurate predictor 
of recurrence risk than margin status in a recent meta-analysis (Arbyn et al., 2017). 
The mechanism underlying late recurrence is not well understood, but disease or 
hrHPV hidden in endocervical crypts has been suggested, and reactivated latent 
infections seem a plausible explanation (Reich and Regauer, 2015). 
 
Because of the residual or recurrent disease risk, guidelines recommend follow-up 
after treatment for CIN before returning women to routine screening. Finnish 
Current Care Guidelines advocate cytology and hrHPV testing six months after 
treatment. The guidelines recommend cytology and hrHPV testing two years after 
treatment, even in cases where both results were negative at six months (Cytological 
abnormalities: Finnish Current Care Guidelines (online)., 2019). A British study, 
however, concluded that return to routine screening was safe after treatment if 
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cytology was normal and the hrHPV test negative at six months (Kitchener et al., 
2008). 
 
Long-term risk of recurrent disease after active surveillance of regressed low-grade 
abnormalities is not yet well established. An Australian retrospective study 
comprising a median of four years of follow-up found the recurrence risk of 
untreated, actively surveilled CIN1 or 2 in young women to be 12% and 17%, 
respectively (Wilkinson et al., 2015).  
2.3.2 VAGINAL INTRAEPITHELIAL NEOPLASIA 
2.3.2.1 Classification 
The vagina is covered with stratified squamous epithelium that can also be infected 
by HPV (Vuyst et al., 2009). Vaginal intraepithelial neoplasia (VAIN) is classified in a 
similar fashion as CIN based on the thickness of abnormal cells in the epithelium. The 
previous three-tier classification (VAIN1, 2, 3) was replaced in 2014 with vaginal HSIL, 
including VAIN2 and 3, and vaginal LSIL, including VAIN1 and HPV atypia/atypia 
condylomatosa of the vaginal epithelium (WHO, 2003, 2014). HPV-related cancer of 
the vagina is mostly squamous cell carcinoma. 
2.3.2.2 VAIN epidemiology and natural history 
VAIN is, overall, much less common than CIN with an annual incidence rate of 0.2-0.3 
per 100 000 women (Henson and Tarone, 1977; Sillman et al., 1997). The low 
incidence of VAIN makes comprehensive research difficult. Predisposing factors to 
VAIN are immunosuppression and a history of HPV-related genital disease, with the 
possibility of concomitant disease (Sillman et al., 1997; Gunderson et al., 2013; 
Jentschke et al., 2016). VAIN is more common in peri- or postmenopausal women in 
comparison to CIN (Gunderson et al., 2013; Cong et al., 2018). 
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VAIN is slow to progress, but high-grade VAIN has been estimated to have 
approximately a 10% risk of progressing to invasive vaginal cancer (Sillman et al., 
1997; Rome and England, 2000). Approximately 70% of vaginal carcinomas are HPV 
positive (Arbyn, de Sanjosé, et al., 2012). Incidence of vaginal carcinoma has been 
increasing in Finland and other countries also for an unknown reason (Finnish Cancer 
Registry, no date). Spontaneous regression of VAIN also occurs, and low-grade VAIN 
can also be considered a sign of productive HPV infection that can be managed with 
active surveillance (Aho et al., 1991; Massad, 2008; Cytological abnormalities: Finnish 
Current Care Guidelines (online)., 2019).  
 
Genotype-specific data on VAIN are scarce, but HPV16 seems to predominate (Lamos 
et al., 2016). An Italian study found the most common genotypes in high-grade VAIN 
to be HPV16 (23.3%), HPV18 (20.7%), and HPV31 (14.2%), reflecting also the 
genotype-distribution of high-grade CIN (Bogani et al., 2017). A study in young 
women in the placebo arm of a vaccine trial found that over 50% of vaginal HSIL was 
associated with HPV16/18 and also nearly 20% of vaginal LSIL (Garland et al., 2018). 
Approximately 50% of vaginal LSIL was associated with non-hrHPV genotypes. 
2.3.2.3 VAIN diagnostics and treatment 
VAIN is mostly asymptomatic. VAIN results often in abnormal cytology, and lesions 
can be visualised with colposcopy, although this is more challenging than in the cervix 
(Boonlikit and Noinual, 2010; Sopracordevole et al., 2018). The vagina has a much 
larger surface area and has to be stretched in multiple directions for complete 
visualisation. Use of iodine can aid identification of abnormal areas. VAIN presents in 
a substantial proportion of cases after hysterectomy, especially if it has been 
performed for CIN or cervical cancer (Rome and England, 2000). Most VAIN occur in 
the upper third of the vagina, and multifocal lesions are common (Aho et al., 1991; 
Boonlikit and Noinual, 2010). Diagnosis of VAIN should be based on colposcopically 
guided biopsies. Small studies have reported occult vaginal cancer associated with 
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high-grade VAIN in 12-28%, emphasising the need for adequate and even multiple 
biopsies of suspicious areas (Hoffman et al., 1992; Indermaur et al., 2005). 
 
VAIN treatment is also challenging because of the anatomy and the possibility of 
multifocal disease (Gurumurthy and Cruickshank, 2012). Many different approaches 
in treatment have been used. Historically, surgery (partial or total vaginectomy) 
aiming at removal of the vaginal mucosa has been performed. Total vaginectomy 
causes significant morbidity and should be reserved for special circumstances 
(Gurumurthy and Cruickshank, 2012). Studies have concluded that upper 
vaginectomy has a position as treatment in unifocal disease of the vaginal vault, at 
least in patients in whom shortening of the vagina might not cause an issue and 
where invasion cannot be ruled out (Diakomanolis et al., 2002; Indermaur et al., 
2005; Gurumurthy and Cruickshank, 2012).  Upper vaginectomy can also be 
performed with loop excision (Fanning, Manahan and McLean, 1999). Smaller 
excisional procedures or laser excision can also be carried out (Julian, O’Connell and 
Gosewehr, 1992; Cheng et al., 1999; Rome and England, 2000; Sopracordevole et al., 
2017; Bogani et al., 2018). 
 
Laser vaporisation or ablation is used often as first line of treatment, because it is 
more useful in multifocal disease and can be performed in an outpatient setting (Kim 
et al., 2009; Gunderson et al., 2013; Perrotta et al., 2013; Wang et al., 2014; 
Jentschke et al., 2016). This, however, does not allow for additional histological 
diagnosis in contrast to excisional procedures and should be limited to cases where 
the lesion can be fully visualised. Internal radiation therapy (brachytherapy) has also 
been used. Small studies with different protocols have reported good success rates 
(Graham et al., 2007; Blanchard et al., 2011).  It should not be considered as a first 
line treatment due to the adverse effects of radiation (Gurumurthy and Cruickshank, 
2012).  
 
A topically applied chemotherapeutic antimetabolite 5-fluorouracil (5-FU) has also 
been used. A recent meta-analysis of 14 moderate quality studies of 358 women 
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found a good success rate with some adverse effects (Tranoulis et al., 2018).  An 
earlier study, however, has reported chronic vaginal ulcerations requiring surgical 
treatment (Krebs and Helmkamp, 1991). Topically applied immunomodulator 
imiquimod has been used in small, nonrandomised studies with equal success rates 
to other therapeutic options (Buck and Guth, 2003; Haidopoulos et al., 2005; Lin et 
al., 2012; de Witte et al., 2015). Both of these medical treatments are used in VAIN 
off label (Gurumurthy and Cruickshank, 2012). 
 
Conclusive overall outcomes of different treatment methods are difficult to provide 
due to the small number of patients and varying follow-up in individual studies or 
case series. Success rates generally vary between 60-100% for every treatment 
method in one treatment round (Gurumurthy and Cruickshank, 2012). Equally, a 
major issue in VAIN treatment is the high residual disease and recurrence rate, 
leading to repeated treatments. Risk factors for recurrence are hrHPV persistence 
and multifocal disease, and it appears that younger patients with disease involving 
the vaginal vault have a higher recurrence risk (Dodge et al., 2001; Frega et al., 2007; 
Kim et al., 2009). Additionally, all current treatment methods can have significant 
adverse effects, some of which are long term (especially vaginectomy, radiation 
therapy, 5-FU). Finnish Current Care Guidelines suggest follow-up with colposcopy 
six months after treatment (mostly laser vaporisation) with frequency of 
colposcopies determined by post-treatment hrHPV status and follow-up lasting at 
least three years in all circumstances before return to routine screening (Cytological 
abnormalities: Finnish Current Care Guidelines (online)., 2019). 
2.3.3 VULVAR INTRAEPITHELIAL NEOPLASIA 
The vulva has two main types of intraepithelial neoplasia: one type is related to HPV 
(usual vulvar intraepithelial neoplasia, uVIN) and the other (differentiated VIN, dVIN) 
to chronic dermatoses, including lichen sclerosus (del Pino, Rodriguez-Carunchio and 
Ordi, 2013; Halonen et al., 2017). uVIN and associated squamous cell carcinoma 
occur at a younger age than dVIN and associated squamous cell carcinoma (de 
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Sanjosé et al., 2013). Overall, approximately 90% of VIN is associated with HPV 
(especially HPV16, 31, and 18), but only 30% of vulvar squamous cell carcinoma is 
HPV positive (Arbyn, de Sanjosé, et al., 2012; de Sanjosé et al., 2013). The incidence 
of VIN has been reported to be increasing, although VIN is not as common as CIN 
(Judson et al., 2006). 
2.4 HPV-RELATED DISEASE OF OTHER ANATOMIC SITES 
HPV-related disease is not restricted to the female genital tract, since hrHPVs can 
infect any mucosal epithelium. Overall, 600 000 of annual incident cancer cases (4.8% 
of global cancers) can be currently attributed to HPV (Arbyn, de Sanjosé, et al., 2012; 
Forman et al., 2012). HPV is recognised as a cause in approximately 70% of vaginal 
and anal cancers and in 40% of vulvar and penile cancers (Arbyn, de Sanjosé, et al., 
2012). Increasing numbers of cancers are recognised to have an association with HPV 
infection, such as oropharyngeal cancer, of which approximately 20-55% are 
attributed to HPV, depending on the exact anatomic site (Ndiaye et al., 2014). Other 
cancers, such as colorectal, lung, urinary bladder, and prostate cancer, have been 
implicated to have an association with HPV, but evidence is still accumulating (IARC, 
2012).  
 
Cervical cancer and precursors, however, currently remain the disease with the 
strongest correlation to HPV infection and the possibility of secondary prevention by 
screening and treating premalignant disease. For the time being, other HPV-related 
disease control will be more dependent on primary prevention with vaccine 
immunity (Chaturvedi, 2010).  
 
2.5 EPIGENETICS 
Epigenetics means regulatory mechanisms of gene expression beyond the genetic 
sequence encoded in DNA. Epigenetic mechanisms can respond to external 
 45 
environmental stimuli, leading to dynamic gene expression patterns (Lorincz, 2016). 
This kind of regulation of gene expression has been found to be important in foetal 
development, ageing, and death (Issa, 2000; Robertson, 2005). Epigenetic regulation 
can change in the course of a lifetime, while the DNA sequence remains generally the 
same, although sporadic mutations do occur. Epigenetic marks, however, can also be 
heritable and lead to genomic imprinting, i.e., epigenetically programmed gene 
expression patterns in offspring (Reik and Walter, 2001). 
2.5.1 DNA METHYLATION 
Methylation of DNA is the main mechanism through which gene expression is 
regulated epigenetically in mammals (Bird, 2002). Other more complex mechanisms 
involve intracellular protein complexes and post-translational methylation of histone 
proteins (Bird, 2002). DNA is most commonly methylated by the addition or removal 
of a methyl group (CH3) to or from an aromatic ring of the nucleotide cytosine (C), 
followed directly by guanine (G) at so-called CpG sites (Bird, 2002). CpG islands 
comprising many CpG sites are mostly found close to promoter DNA regions 
responsible for gene transcription (Bird, 1986; Illingworth and Bird, 2009). 
Hypermethylation can lead to condensation of stretches of DNA, preventing its 
transcription, and hypomethylation can lead to increased transcription (Lorincz, 
2016). 
2.5.2 DNA METHYLATION, CARCINOGENESIS, AND CANCER  
 
The role of methylation in carcinogenesis has been, and continues to be, extensively 
studied. In the past carcinogenesis was primarily seen as the clustering of 
unfortunate sporadic mutations in DNA, leading to the activation of oncogenes and 
deactivation of tumour suppressor genes, which could be further enhanced by an 
individual’s genetic predisposing factors (Knudson, 1971). It is recognised now that, 
in fact, epigenetic mechanisms appear to be equally important in malignant 
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transformation and can lead to the same change in gene expression as actual 
mutations (Shen and Laird, 2013; Witte, Plass and Gerhauser, 2014). 
 
The first findings in the 1980s were of mass hypomethylation of many CpG sites in 
malignant colorectal tumours in comparison to normal tissue (Feinberg and Tycko, 
2004). A similar difference in methylation was seen between benign and 
premalignant colorectal tumours (Goelz et al., 1985). This hypomethylation results in 
the activation of oncogenes and causes overall genomic instability (Lorincz, 2014). 
Hypermethylation of specific CpG islands, however, causes silencing of tumour 
suppressor genes and contributes to neoplastic transformation (Feinberg and Tycko, 
2004). This kind of epigenetic change could be reversible, whereas actual silencing 
mutations in the genetic code currently are not (Lorincz, 2016). 
 
Studies of methylation patterns, methylomics, are currently widely incorporated into 
the study of cancer genomics in a variety of malignant diseases (Witte, Plass and 
Gerhauser, 2014). Currently, methylation can be seen to show promise in cancer risk 
evaluation, early detection, prognosis, and therapeutic response. For example,  
aberrant methylation patterns in non-small cell lung cancer patients could be 
identified in sputum three years prior to clinical diagnosis (Palmisano et al., 2000). 
Another study of several types of solid malignant tumours and haematopoetic 
malignancies has shown hypermethylation of promoter region DNA to be present 
already in precancerous or normal tissue (Sproul et al., 2012). Further research is still 
ongoing and needed before clinical use for the majority of possible methylation 
applications.  
2.5.3 DNA METHYLATION IN CIN AND CERVICAL CANCER 
DNA methylation has also been a focus of research interest in cervical neoplasias, 
because none of the current diagnostic methods or known risk factors can explain 
why neoplastic transformation happens in some HPV infected individuals and not in 
others. Both viral and host genome methylation have been investigated. 
 47 
 
Widespread hypomethylation was seen initially in the HPV16 genome and overall 
with correlation to neoplasia severity (Badal et al., 2003; de Capoa et al., 2003). 
Specific HPV16 CpG sites of interest were identified later on, and hypermethylation 
was seen with an increasing severity of lesions (Mirabello et al., 2012, 2013; Lorincz 
et al., 2013). Furthermore, CpG targets in other hrHPV genotypes and also a plethora 
of host genes able to differentiate between CIN grades and cancer have been 
identified (Wentzensen et al., 2012; Kalantari et al., 2014; Louvanto et al., 2015; 
Clarke et al., 2017). FAM19A4, a host gene, has also been been shown to be more 
often positive in methylation testing in high-grade cervical disease when the hrHPV 
infection has persisted longer (De Strooper et al., 2014). In a British nested case 
control study within a screening trial, DNA methylation in  women without cytological 
abnormalities showed aberrant patterns in those who were subsequently diagnosed 
with CIN2+ (Teschendorff et al., 2012).  
 
Based on these results, viral and/or host DNA methylation have been seen to show 
promise in development of a biomarker test for the accurate detection and 
prediction of high-grade cervical disease (Cuschieri et al., 2018). A triage test for 
hrHPV screening-positive women is also called for because of the low specificity of 
hrHPV testing (Cuzick et al., 2012). Currently, cytology is commonly used as a triage 
test, but this suffers from subjectivity of interpretation and modest sensitivity even 
if combined with immunostaining (p16, Ki67) (Cuzick et al., 2012; Cuschieri et al., 
2018). HPV genotyping (HPV16/18) has also been proposed to solve this issue, but it 
appears to perform similarly to cytology (Castle, Stoler, et al., 2011). A recent study 
from the United States, however, shows dual staining (DS) with p16 and Ki67 to 
outperform cytology in triage of hrHPV-positive women and extended follow-up 
without colposcopy to be safe in DS and HPV16/18 genotyping-negative women 
(Wentzensen et al., 2019). A major advantage of a methylation-based test would be 
the objectivity of interpretation in contrast to methods relying on microscopy of 
cytological specimens (Cuzick et al., 2012; Cuschieri et al., 2018). Viral and host CpG-
site methylation have been studied in various combinations and generally have been 
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found to have a sensitivity of a little under 90% and specificity of 50-70% in detecting 
CIN2/3+, which to date is not performing better than its proposed counterparts  
(Lorincz, 2016). 
 
A DNA methylation test, QIAsure Methylation Test (Qiagen, Venlo, Netherlands), is 
commercially available for triage of hrHPV-positive women. It tests for 
hypermethylation of the host genes FAM19A4 and hsa-mir124-2 (De Strooper et al., 
2016) and has been shown to have a sensitivity of 67% in detecting CIN3 and 100% 
of cervical cancer also in self-sampling (De Strooper et al., 2016; Luttmer et al., 2016). 
The combination of HPV16/18 genotyping results was shown to increase sensitivity 
further, albeit with a commensurate loss of specificity. 
 
A DNA methylation classifier (S5) has been developed comprising the late regions of 
HPV16, 18, 31, 33, and the promoter region of a human tumour suppressor gene 
EPB41L3 (Brentnall et al., 2014). It has been shown to perform well as a triage test 
for hrHPV screening-positive women and outperformed HPV16/18 genotyping in 
detection of CIN3+ with sensitivities of 0.84 (95% CI 0.62-0.94) and 0.58 (95% CI 0.36-
0.77), respectively (p=0.04) (Lorincz et al., 2016). The corresponding specificities 
were 0.63 (95% CI 0.58-0.68) and 0.69 (95 % CI 0.64-0.74), respectively (p=0.07). In 
another study it also outperformed abnormal cytology in combination with 
HPV16/18 genotyping in detecting prevalent CIN2/3 and did not fail to detect any of 
the prevalent or incident cancer cases within the follow-up period (Cook et al., 2018).  
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3 AIMS OF THE STUDY 
The goal of this thesis was to characterise the HPV genotypes causing gynaecological 
morbidity in Finnish women prior to prophylactic vaccinations, and to assess novel 
approaches in evaluation and treatment of cervical and vaginal intraepithelial 
neoplasia. 
 
The aims of the individual studies were: 
 
1. To assess the age-specific HPV genotype distribution in Finnish women with 
cytological abnormalities that cause clinical morbidity 
 
2. To evaluate the clinical course of untreated CIN2 and adherence to active 
surveillance protocols 
 
3. To assess the performance of a DNA methylation classifier in predicting 
clinical outcomes of untreated CIN2 
 
4. To evaluate the efficacy of self-administered vaginal imiquimod in treatment 
of VAIN 
 
Subjects and methods 
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4 SUBJECTS AND METHODS 
4.1 SUBJECTS (STUDY I, III, IV) 
Three studies (I, III, IV) were conducted in separate patient cohorts recruited at the 
Colposcopy Centre of the Department of Obstetrics and Gynecology in Helsinki 
University Hospital. Table 7 describes the characteristics of the prospective studies 
(I, III, IV). The studies have been granted approval to be carried out by the Hospital 
District of Helsinki and Uusimaa and the recruited women gave written informed 
consent in accordance with the Declaration of Helsinki. All studies were registered in 
the International Standard Randomised Controlled Trial Number (ISRCTN) registry.  
 
The first cohort (study I) recruited a total of 1302 patients 18 years of age or older 
who had been referred to colposcopy for abnormal cytology (Table 8). Recruitment 
started in January 2014 and ended in May 2016. The study was carried out in 
collaboration with Karolinska Institute, Stockholm, Sweden. The study protocol was 
approved by Helsinki University Hospital’s Ethical Committee (130/13/03/03/2013). 
 
The second prospective study (study III) was performed in a cohort study that 
recruited women 18 to 30 years of age with histologically confirmed CIN2. 
Recruitment started in September 2013 and finished in December 2018. The first 149 
patients with at least two 6-monthly follow-up visits completed were included in the 
current study, and the study was carried out in collaboration with the Center for 
Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University 
of London, UK, and the Karolinska Instute, Stockholm, Sweden. The study protocol 
was approved by Helsinki University Hospital’s Ethical Committee 
(131/13/03/03/2013). 
 
The third prospective study (study IV) was a randomised, controlled trial (RCT) that 
recruited patients 18 years of age or older with histologically confirmed VAIN2-3 or 
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VAIN1 that had persisted for two years. The study recruited 30 patients between 
December 2012 and May 2015. The study protocol was approved by Helsinki 
University Hospital’s Ethical Committee (385/13/03/03/2012) and the Finnish 
Medicines Agency Fimea (EudraCT 2012-005377-31). 
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Table 7. Characteristics of the prospective studies (I, III, IV) 
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Table 8. Characteristics of 1279 women referred to colposcopy for abnormal cytology (study I).  
 
4.2 METHODS (STUDY I, III, IV) 
4.2.1 COLPOSCOPY AND LOCAL TREATMENT 
Colposcopies were performed with 5% acetic acid with or without Lugol’s iodine 
solution, depending on the colposcopist’s preference. A senior colposcopist with 
national accreditation or at least 100 colposcopies performed annually was always 
present at colposcopy. Cytology and punch biopsies were taken at the discretion of 
the colposcopist, and routine punch biopsies were taken at the final visit of studies 
III and IV. An extra endocervical brush sample was obtained for HPV genotyping in 
All
N=1279
<30
N=339
30-44.9
N=614
≥45
N=326
Age median 
(range)
35.1 (19.2-83.7) 26.1 (19.2-29.9) 35.2 (30.0-44.9) 51.4 (45.0-83.7)
Referral cytology % N % N % N % N
Repeat ASC-US 10.6 135 14.5 49 6.0 37 15.0 49
LSIL 39.3 502 26.6 90 44.6 274 42.3 138
ASC-H 24.9 318 31.6 107 23.6 145 20.3 66
HSIL 19.8 253 25.1 85 21.2 130 11.7 38
AGC-NOS 3.4 43 1.5 5 2.6 16 6.8 22
AGC-FN 2.2 28 0.9 3 2.0 12 4.0 13
Cervical histology
NILM 30.0 383 20.9 71 24.6 151 49.4 161
LSIL 29.3 375 31.3 106 30.3 186 25.5 83
CIN2 18.6 238 28.0 95 17.9 110 10.1 33
CIN3 17.7 226 15.9 54 22.8 140 9.8 32
AIS 1.5 19 1.5 5 1.8 11 0.9 3
Cervical cancer 1.6 20 0.9 3 1.3 8 2.8 9
No sample 1.4 18 1.5 5 1.3 8 1.5 5
LLETZ 37.2 476 24.2 82 43.8 269 38.3 125
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studies I and III, and endocervical cells obtained with the sample were also used for 
methylation analyses in study III. An hrHPV test (endocervical or from the vaginal 
vault in cases with previous hysterectomy) was taken in study IV at the recruitment 
and exit visits. Colposcopists were unaware of the HPV genotyping and S5 DNA 
methylation results. 
 
LLETZ (study I and III) was performed under local anaesthesia and colposcopic 
guidance at the outpatient clinic. Laser vaporisation of VAIN (study IV) was also 
performed under local anaesthesia and colposcopic guidance at the outpatient clinic 
with carbon dioxide laser 6-12W continuous beam to a depth of 2 mm with 2 mm 
margins. 
 
The study I participants were examined, treated, and followed-up according to 
Finnish Current Care Guidelines. Figure 3 presents a flow chart of study visits in study 
III. Decisions to treat at 24 months for persistence in cases of CIN1/LSIL were made 
on an individual basis in study III, taking into account the cytological finding and 
colposcopic appearance. Figure 4 presents a flow chart of study IV.
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Figure 3 Flow chart on the cohort study on expectant management of CIN2 in young women (study 
III). Eighty-six women have completed the study (either progression treated or finished 24 
months of follow-up). Follow-up is still ongoing for 63 women. Among the 19 women with 
persistence at 24 months, seven LLETZ were performed with CIN2 histology found in the 
cone, and the remaining 12 are followed-up according to guidelines. Redrawn from 
Louvanto et al. Clin Infect Dis. 2019 Jul 25. doi: 10.1093/cid/ciz677 
Cohort of expectant management in young women with CIN2
N=149
Baseline visit: colposcopy and cervical brush sample
6 MONTH VISIT
LLETZ
12 MONTH VISIT
18 MONTH VISIT
24 MONTH STUDY EXIT VISIT
Progression
≥ CIN3
N=5
Persistence           
CIN1, CIN2
N=52
Regression           
<CIN1
N=59
Regression           
Normal
N=42
Persistence
CIN1, CIN2
N=19
Progression
≥ CIN3
N=4
Regression           
<CIN1
N=46
Persistence           
CIN1, CIN2
N=86
Progression
≥CIN3
N=14
Regression           
<CIN1
N=24
Persistence           
CIN1, CIN2
N=26
Progression
≥ CIN3
N=2
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Figure 4 Flow chart on the progress of a randomised trial on VAIN treatment (study IV). Redrawn 
from Tainio et al. Int J Cancer 2016 Nov 15;139(10):2353-2358. 
4.2.2 RANDOMISATION AND TREATMENT (STUDY IV) 
Study IV’s three treatment groups were vaginal self-administered imiquimod, laser 
vaporisation, and active surveillance. The patients were randomised 1:1:1 by 
computer-assisted, permuted-block randomisation with random block sizes of four 
to six, and the investigators did not participate in the process. Allocation 
concealment was achieved by sequentially numbered, sealed opaque envelopes. The 
study visits for all arms were at 4, 8, and 16 weeks after the enrolment visit. 
 
Randomised trial of VAIN treatment
Assessed for eligibility
N=33
Randomised
N=30 
(N=3 declined participation)
Received
allocated
treatment
N=5
Received
conventional
treatment
upon request
N=4
Received 
allocated 
treatment
N=10
Received 
allocated 
treatment           
N=9
Halved dose
N=1
Analysed
N=10
Analysed
N=10
Analysed
N=9
Allocated to 
imiquimod 
treatment
N=10
Allocated to
laser 
treatment
N=10
Allocated to 
expectant
management
N=10
Lost to 
follow-up
N=0
Lost to 
follow-up
N=0
Lost to 
follow-up
N=1
(death of 
unrelated
causes)
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Patients allocated to active surveillance had no other intervention than punch 
biopsies at the baseline and exit visit (16 weeks) and also at the 8-week visit if new 
lesions were suspected. Laser vaporisation was performed in the laser group at the 
recruitment visit, as previously described.  
 
12.5 mg of imiquimod was manufactured into vaginal suppositories (inactive binding 
materials: macrogol 400 1.35 g and macrogol 6000 0.9 g) by the Pharmacy of Helsinki 
University Hospital. Patients self-administered the total of 14 suppositories in the 
evening before bedtime over a period of eight weeks. The dose was 12.5 mg weekly 
for the first two weeks, and 12.5 mg doses twice a week 3-4 days apart in the 
remaining six weeks.  
 
The patients received all suppositories from the investigators with written and oral 
instructions for use and storage (room temperature) along with a diary for recording 
use and any adverse effects (separate fields for application dates, flu-like symptoms, 
fever, local irritation, lower abdominal pain and other symptoms). They were 
instructed to halve the suppositories longitudinally and continue the treatment with 
half a dose (6.25 mg) if adverse effects were not tolerable after medication 
(paracetamol and/or non-steroidal anti-inflammatory drug (NSAID)). 
4.2.3 COLLECTION OF CLINICAL DATA 
Data on referral reasons, patient background (chronic illnesses, current medications, 
cigarette smoking, parity, contraception, hormone replacement therapy, previous 
cytological and histological gynaecological findings and treatments, history of 
sexually transmitted diseases), and clinical findings (RCI, colposcopic diagnosis) were 
retrieved from the structured electronic colposcopy database. Age at recruitment 
was recorded. 
 
Data on cytological and histological samples and diagnoses taken at visits were 
retrieved from the hospital’s electronic patient records. Cytology was reported 
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according to the Bethesda system. A shift was made from the WHO 2003 
histopathological classification to the WHO 2014 classification during the study 
periods. The institution’s pathologists, however, reported HSIL at different anatomic 
sites, also according to the WHO 2003 classification: cervical HSIL as either CIN2 or 
CIN3 and vaginal HSIL as VAIN2 or VAIN3. Reporting of low-grade lesions shifted from 
HPV atypia, atypia condylomatosa, etc., and CIN1 or VAIN1 to LSIL. Studies III and IV’s 
data were collected according to the WHO 2003 classification, and study I grouped 
low-grade lesions as LSIL. During the study period hrHPV testing in routine clinical 
practice was performed with Hybrid Capture 2 (Digene Corporation, Gaithersburg, 
MD, USA; Qiagen, Venlo, Netherlands) until April 2014 and thereafter with Aptima 
(Hologic, Marlborough, MA, USA). Study IV analysed the hrHPV test results. 
 
The worst histological diagnosis was included in the analysis in study I if LLETZ was 
performed based on punch biopsy results from the recruitment visit within 1-2 
months. The baseline histological diagnosis of CIN2 was re-reviewed by an expert 
pathologist in study III. The worst histological diagnosis for a time-point from punch 
biopsies or LLETZ cone was also recorded. 
 
The patients reported adverse effects and use of imiquimod treatment in a separate 
written form (study IV). 
4.2.4 LABORATORY ANALYSES 
4.2.4.1 Sample handling and HPV genotyping (study I, III) 
The cells collected with the endocervical brushes in specimen transport medium 
(STM, Qiagen GMBH, Hilden, Germany) were stored immediately at -20° C and later 
divided into three aliquots without adding any medium and stored at -80° C.  
 
One aliquot was sent frozen to the Karolinska Institute for HPV genotyping. DNA 
was extracted from the samples, and a modified GP5+/6+ primer set was used for 
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polymerase chain reaction (PCR) , as described previously (Söderlund-Strand, 
Carlson and Dillner, 2009). Genotyping was performed with the Bioplex 200 
Luminex system (Bio-Rad, California). 
4.2.4.2 DNA methylation analyses (study III) 
One aliquot of the endocervical cells stored in STM was sent frozen to the Center for 
Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University 
of London, for DNA methylation analyses. DNA was extracted with the QIAamp DNA 
Mini Kit (Qiagen Inc, Hilden, Germany). Two hundred nanograms of DNA were used 
in the bisulfite conversion reactions using the EZ DNA methylation kit (Zymo 
research, Irvine, USA) to convert unmethylated cytosines to uracil. Converted DNA 
(equivalent of 1600 cells per sample) were amplified by methylation-independent 
PCR primers, and the amplicons were tested by pyrosequencing for DNA methylation 
of EPB41L3 and the late regions of HPV16, HPV18, HPV31, and HPV33. 
4.2.5 OUTCOME PARAMETERS 
hrHPV genotypes were grouped for analyses in study I as HPV16/18+, other hrHPV+ 
(HPV31/33/35/39/45/51/52/56/58/59/66/68+), hrHPV not directly targeted by 
prophylactic HPV vaccines (non-vaccine hrHPV+: HPV35/39/51/56/59/66/68+), 
other HPV than high-risk (only low-risk HPV: 
HPV6/11/30/40/42/43/53/61/67/69/70/73/74/81/83/86/87/89/90/91+), and HPV 
negative. Other hrHPV and non-vaccine hrHPV were considered positive only if 
HPV16/18 were not present, and only low-risk HPV was positive only if hrHPVs were 
not present. The individual HPV groups were positive if any or multiples of the 
included types in the individual groups were present. 
 
Cervical histological findings were grouped in study I as less than HSIL (<HSIL), 
including NILM and LSIL; HSIL or worse (HSIL+), including CIN2, CIN3, AIS, squamous 
cell carcinoma, and adenocarcinoma of the cervix; CIN3+, including CIN3 and 
squamous cell carcinoma; and adenocarcinoma in situ or worse (AIS+), including AIS 
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and adenocarcinoma. Women were grouped into three categories based on age: <30 
years of age, 30-44.9 years of age, and ≥45 years of age. 
 
Study III outcomes were divided as regression, persistence, and progression based 
on histological diagnosis. CIN2 regression was defined as <CIN1 according to the 
WHO 2003 classification. CIN1 and CIN2 were considered as persistence and ≥CIN3 
as progression. Cases with high grade cytology (ASC-H, HSIL) at follow-up time points 
but <CIN1 histology were classified as persistence. For some analyses, women with 
persistence were grouped together with regression or progression, respectively. HPV 
genotyping results were recorded as a binary, with women positive in genotyping 
either for HPV16 or 18 or both classified as positive (HPV16/18+) and as negative if 
neither was found (HPV16/18-), and similarly for HPV16/18/31/33+ and 
HPV16/18/31/33-. The S5 methylation classifier was defined with percentages of the 
methylation measured in biomarker variables as 30.9(EPB41L3) + 13.7(HPV16L1) + 
4.3(HPV16L2) + 8.4(HPV18L2) + 22.4(HPV31L1) + 20.3(HPV33L2). Cut-offs for S5 were 
set at the previously validated cut point of S5 = 0.8 or at the upper tertile of S5 
defined as any value within the upper 1/3 of methylation values identified for each 
methylation biomarker in the specific outcome category. 
 
Study IV considered regression as partial if VAIN2-3 regressed to VAIN1. Complete 
regression was defined as <VAIN1 according to the WHO 2003 classification. 
Persistence was defined as VAIN2-3 at the end of the study. Progression for VAIN2 
was defined as ≥VAIN3 and as vaginal carcinoma for VAIN3. hrHPV clearance was 
defined as a positive hrHPV test in the baseline visit and a negative test at the exit 
(16 week) follow-up visit; persistence was defined as a positive hrHPV test at both 
time points. 
4.2.6 STATISTICAL ANALYSES 
Study I estimated risk ratios (RR) of being HPV genotype group positive between 
different age groups according to histological findings using binomial logistic 
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regression; the youngest age group (women <30 years of age) was set as the referent 
group. 
 
Study III compared differences in baseline characteristics in the different clinical 
outcome groups (regression, persistence, progression) with Mann-Whitney or 
Fisher’s exact test or nonparametric test for trend, as applicable. The associations of 
mean methylation level or the upper tertile level of different methylation markers 
and various clinical outcome comparisons were evaluated with unconditional logistic 
regression odds ratios (OR) and 95% confidence intervals. Multivariable models of 
logistic regression were used to evaluate confounding factors in methylation and 
outcome comparisons. Receiver operator characteristic (ROC) analysis by comparing 
area under the curve (AUC) was used to test the performance of the methylation 
marker and screening protocols. Missing baseline DNA methylation status (n=8) of 
HPV16 were imputed with zero for HPV16-negative samples (n=5) and by the median 
for HPV16 positive samples for HPV16-positive women (n=3). Missing values for 
EPB41L3 (n=8) were imputed by the median independent of their HPV genotyping 
result. Eight women without HPV genotyping results were imputed as HPV negative. 
 
Study IV compared the baseline characteristics and findings between the three arms.  
The cytological and histological findings and hrHPV status were compared at 16 
weeks. Additional comparisons between two individual arms were performed 
(imiquimod vs. laser, imiquimod vs. expectant management, and laser vs. expectant 
management). Frequency tables were analysed using the Chi 2 test or Fisher's exact 
test for categorical variables, and means of continuous variables were analysed using 
nonparametric (Kruskal-Wallis) tests for two and multiple independent samples, 
respectively. The results were analysed according to intention-to-treat analyses. 
 
In studies I and III statistical analyses were done in STATA version 15 (STATA Corp., 
College Station, TX) and in study IV STATA version 13 was used (STATA Corp., College 
Station, TX). 
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4.3 ELIGIBILITY CRITERIA (STUDY II) 
Study II was a systematic review and meta-analysis carried out in national and 
international collaboration (study registration PROSPERO2014: CRD42014014406). 
Original studies were included that reported on outcomes of histologically diagnosed 
CIN2 not treated at diagnosis. Other inclusion criteria were expectant management 
for three or more months and a follow-up diagnosis with either histology and/or 
cytology. A histological diagnosis was always preferred to a cytological one. Studies 
on pregnant women, HIV-positive women, studies in which fewer than 10 patients 
completed follow-up, studies without a defined follow-up period or merging CIN2 
with CIN1 or CIN3, and studies published in other languages than English were 
excluded. 
4.4 METHODS (STUDY II) 
4.4.1 LITERATURE SEARCH, DATA EXTRACTION, AND RISK OF BIAS APPRAISAL 
Three databases (Medline, Embase, and the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL)) were searched for publications between 1 January 1973 
and 20 August 2016. Reference lists of included studies were also hand searched. 
Abstracts were screened independently in duplicate, and full texts of eligible studies 
from screened abstracts were screened similarly. Figure 5 presents a flow chart of 
the screening process.  
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Figure 5 Flow chart of the publication evaluation process in a systematic review and meta-analysis 
of the clinical course of untreated CIN2 (study II). Redrawn from Tainio et al. BMJ. 2018 Feb 
27;360:k499. 
 
Data extraction and risk of bias assessment were performed independently in 
duplicate by two investigators. Progression, persistence and regression rates from 
each study were extracted, as well as the name of the first author, year of 
publication, the design and setting, the total number of participants, the number of 
participants with the outcomes of interest at different time points, geographical 
region, and the number of baseline hrHPV- or HPV16/18-positive women, or both. 
  
6275 
Records identified
250
Full-text publications
assessed for 
eligibility
6025 
Abstracts excluded
7
Publications are duplicates of same patient cohort
43
Publications fulfilling 
eligibility criteria 
included
213 
Publications excluded
Not enough untreated CIN2 patients, n=93
Rates of outcomes of interest cannot be calculated, n=80
Initial diagnosis of CIN2 not confirmed by histology, n=10
Not an original study or systematic review, n=8
Separate data on CIN2 not reported, n=7
No report of method for confirming end of study findings, n=3
Mathematical model, not original data, n=3
Other than English language, n=3
Duplicates, n=3
Other, n=3
36
Study cohorts 
included in
meta-analysis
6
Publications added from references of 
included publications
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Risk of bias was assessed using a modified version of the Cochrane Collaboration’s 
risk of bias tool by evaluating each study according to five criteria (Table 9). 
Table 9. Risk of bias assessment tool and definitions 
 
For each risk of bias criterion, studies were judged to have either a high or a low risk 
of bias. Studies were classified at high risk of bias overall if at least one criterion was 
at high risk of bias. 
4.4.2 OUTCOME PARAMETERS 
Study II used the definition of progression, persistence, and regression given by the 
authors of the original publications in each study. Recognising that there would be 
heterogeneity in definitions between studies, regression and persistence definitions 
were classified into two groups: “strict” or “lenient” (Table 10). For studies reporting 
more than one outcome definition (strict and lenient), the strict definition was used 
in the main analyses. 
  
Domain Low risk of bias High risk of bias
Assessment of exposure Secure record (e.g. hospital records) Structured interview, self-written 
report
Confirmation of initial 
(CIN2) diagnosis
Histological confirmation Confirmation by cytology, colposcopy 
and/or HPV testing
Assessment of outcome Outcome confirmed with multiple 
methods including histology
Outcome confirmed only with 
cytology, colposcopy or HPV testing
Loss to follow-up Loss to follow-up <10% Loss to follow-up >20% or not 
adequately reported
Representativeness 
of cohort
All eligible (CIN2) cases in a 
predefined time period and 
population included
Not fulfilling low risk criteria, 
predefined age range is not 
considered high risk of bias
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Table 10. Cytological and histological criteria for strict and lenient definitions of regression and 
persistence 
 
 
Progression was defined as histological CIN3 or worse (CIN3+) in 29 studies and as a 
worsening cytological finding during follow-up in the remaining seven. Regression, 
persistence, progression, and default rates were defined as the ratio of the number 
of women with an outcome divided by the number of women attending follow-up at 
that time point. The studies were grouped to the closest time point (3, 6, 12, 24, 36, 
and 60 months of active surveillance) based either on the exact, the median, or mean 
follow-up time. Loss to follow-up was defined as the actual number of women lost to 
follow-up in prospective studies and as the number participants with missing follow-
up data in retrospective studies. 
4.4.3 STATISTICAL ANALYSES 
Pooled proportions for each outcome were meta-analysed separately at the 3, 6, 12, 
24, 36, and 60-month time-points using the metaprop command in STATA. The exact 
binomial score test-based confidence intervals with the Freeman-Tukey double 
arcsine method were used to stabilise the variances for individual studies, where 
many of the proportions were close to the margins of the interval (0 or 100%). 
Heterogeneity between studies was assessed using the I2 metric of inconsistency. A 
single predefined set of sensitivity analyses was performed to explore heterogeneity 
sources. Additional subgroup analyses were performed to further explore the 
heterogeneity sources and differences in summary estimates, including according to 
Strict 
regression
Lenient 
regression
Strict 
persistence
Lenient 
persistence
Cytology Normal ASC-US, LSIL
ASC-US, LSIL, 
ASC-H, HSIL
ASC-H, HSIL
Histology Normal Normal, CIN1 CIN1, CIN2 CIN2
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the age range (studies with only ≤30-year-olds and >30-year-olds, respectively) and 
according to baseline hrHPV or HPV16/18 status. 
 
Analyses were performed in STATA version 13 (STATA Corp., College Station, TX). 
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5 RESULTS 
5.1 AGE-SPECIFIC HPV GENOTYPE DISTRIBUTION 
Study I recruited 1302 women referred for cytological abnormalities; valid HPV 
genotyping results were available for 1279. The most prevalent genotype in the 1279 
women was HPV16 (28.3%), but the prevalence declined steeply with increasing age 
between age groups, as did prevalence of HPV16/18. Conversely, HPV negativity 
increased between age strata (Table 11). 
 
Table 11. HPV genotype and genotype-group distribution in 1279 women referred to colposcopy 
for abnormal cytology (single genotypes irrespective of multiple infections) 
 
Other hrHPV (HPV31/33/35/39/45/51/52/56/58/59/66/68), non-vaccine hrHPV (HPV35/39/51/56/59/66/68), 
only low-risk HPV (HPV6/11/30/40/42/43/53/61/67/69/70/73/74/81/83/86/87/89/90/91) 
 
Altogether, 503 cases of histological HSIL+ were identified (Table 12, Figure 5), and 
56.7% were associated with HPV16/18. There was a pronounced decrease of 
HPV16/18-associated HSIL+ with increasing age: 64.3% in women <30 years of age, 
58.4% (RR 0.91, 95% confidence interval 0.78-1.06) in women 30-44.9 years, and 
35.1% (RR 0.55, 95% CI 0.39-0.75) in women ≥45 years. However, other hrHPVs 
All
n=1279
<30
n=339
30-44.9
n=614
≥45
n=326
% n % n % n % n
HPV type
HPV negative 17.3 221 9.7 33 13.7 84 31.9 104
HPV16 28.3 362 38.6 131 30.9 190 12.6 41
HPV18 5.8 74 7.1 24 5.7 35 4.6 15
HPV31 9.9 126 11.8 40 11.1 68 5.5 18
HPV33 3.9 50 5.6 19 3.6 22 2.8 9
HPV45 4.5 57 4.4 15 5.4 33 2.8 9
HPV52 7.7 98 8.9 30 7.7 47 6.4 21
HPV groups
HPV16/18 33.2 425 44.0 149 35.8 220 17.2 56
Other hrHPV 38.1 487 36.0 122 40.2 247 36.2 118
Non-vaccine
hrHPV
15.2 195 13.9 47 15.0 92 17.2 56
Only low-risk
HPV
11.4 146 10.3 35 10.3 63 14.7 48
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(HPV31/33/35/39/45/51/52/56/58/59/66/68) were associated with 31.9% of HSIL+ 
in women <30 years of age, 36.8% in women 30-44.9 (RR 1.16, 95% CI 0.88-1.52), and 
54.6% in women ≥45 (RR 1.71, 95% CI 1.26-2.33). A similar increase was seen with 
nonvaccine-related genotypes (HPV35/39/51/56/59/66/68). The proportion of HPV-
negative HSIL+ cases increased with increasing age with 6.5% of women ≥45, with 
HSIL+ being HPV negative (RR 5.10, 95 % CI 1.01-25.68).  
 
Table 12. Age-specific HPV group distribution and risk ratios (RR) of HSIL+ with women <30 as the 
referent group 
 
Other hrHPV (HPV31/33/35/39/45/51/52/56/58/59/66/68), non-vaccine hrHPV (HPV35/39/51/56/59/66/68), 
only low-risk HPV (HPV6/11/30/40/42/43/53/61/67/69/70/73/74/81/83/86/87/89/90/91) 
 
 
When separating high-grade squamous disease into CIN2 and CIN3+ similar age-
group specific patterns of HPV group distribution were seen, although CIN3+ was 
overall more commonly associated with HPV16/18 than CIN2 (64.2% and 47.5%, 
respectively) (Figure 5). There were only 25 cases of AIS+, but all cases in women <30 
years of age were associated with HPV16/18, while only a third of the cases in women 
≥45. 
HPV16/18
n=425
Other
hrHPV
n=487
Non-vaccine
hrHPV
n=195
Only low-risk 
HPV
n=146
HPV neg
n=221
n 
(%)
RR 
(95% CI)
n 
(%)
RR 
(95% CI)
n 
(%)
RR 
(95% CI)
n 
(%)
RR 
(95% CI)
n 
(%)
RR (
95% CI)
HSIL+ 
<30
N=157
101 
(64.3)
Ref
50 
(31.9)
Ref
8 
(5.1)
Ref
4 
(2.6)
Ref
2 
(1.3)
Ref
HSIL+ 
30-44.9
N=269
157 
(58.4)
0.91 
(0.78-1.06)
99 
(36.8)
1.16 
(0.88-1.52)
15 
(5.6)
1.09 
(0.47-2.52)
3 
(1.1)
0.44 
(0.10-1.93)
10 
(3.7)
2.9 
(0.65-13.15)
HSIL+ 
≥45
N=77
27 
(35.1)
0.55 
(0.39-0.75)
42 
(54.6)
1.71 
(1.26-2.33)
12 
(15.6)
3.06
(1.30-7.17)
3 
(3.9)
1.53 
(0.35-6.66)
5 
(6.5)
5.10 
(1.01-25.68)
HSIL+ 
Total
N=503
285 
(56.7)
191 
(38.0)
35 
(7.0)
10 
(2.0)
17 
(3.4)
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Figure 6 Age-group specific HPV genotype group distribution in different histological categories. 
Redrawn from Aro et al. Gynecol Oncol. 2019 Aug 154(2):354-359. 
5.2 UNTREATED CIN2 
Thirty-six studies with 3160 women were included in the meta-analysis of the 
clinical course of untreated CIN2 (study II). Seven control arms of randomised 
controlled trials, 16 prospective cohort studies, and 13 retrospective studies were 
included. The mean follow-up in the studies was 16 months (range 3-72 months). 
Half of the studies were considered as low-risk of bias. The most common reasons 
for a high-risk of bias assessment were rate of loss to follow-up (14 studies) and 
vagueness of the description of the follow-up method (five studies). 
 
The regression rate at 24 months was 50% and the progression rate was 18% in the 
main analysis. The regression rate at 24 months was 60% and progression rate only 
11% in a subgroup analysis of women <30 years of age (approximately 1000 women 
for all the outcomes) (Table 13). The rates were 44% and 23%, respectively, in women 
≥30 years of age. 
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Table 13. Pooled rates for outcomes at 24 months in women with untreated CIN2 
 
 
N of studies: number of studies included in analysis; N obs: number of outcomes observed;  
N att: number of women attending follow-up time-point 
 
The progression rates increased with the length of follow-up. The progression rate 
at six months was 13% (4 studies, 42/278 women, 95% CI 8-20%; I2 42%) and 24% at 
36 months (three studies, 105/370 women, 95% CI 12-39%; I2=87%) in the main 
analysis. The vast majority of progressions were to CIN3. Among the 3160 women 
included, 15 cases of AIS were reported (0.5%) and 15 invasive cervical cancers 
were additionally reported (0.5%). Thirteen of these were stage IA1, and two were 
of more advanced stage. 
 
Very few studies reported on outcomes according to baseline hrHPV (three studies) 
or HPV16/18 (two studies) status. hrHPV- and HPV16/18-negative women had a 
low risk of progression at 24 months at 3% (1/23 women, 95% CI 0%-24%; I2=0%) 
and 5% (1/62 women, 95% CI 0%-28%; I2=76%), respectively. 25% of hrHPV-positive 
women and 21% of HPV16/18-positive women progressed at 24 months (38/161 
women 95% CI 14%-38%; I2=51%, and 7/56 women, 95% CI 8%-37%; I2=58%, 
respectively). Overall, most women regressed within 24 months irrespective of 
baseline hrHPV or HPV16/18 status.  
24 months
Regression Persistence Progression
Main analysis
N of studies
N obs/N att
11
819/1470
8
334/1257
9
282/1445
Summary %
(95% CI; I2)
50
(43-57; 77)
32
(23-42; 82)
18
(11-27; 90)
<30-year-olds
N of studies
N obs/N att
4
638/1069
2
226/938
3
163/1033
Summary %
(95% CI; I2)
60
(57-63; 0)
23
(20-26; 97)
11
(5-19; 67)
≥30-year-olds
N of studies
N obs/N att
7
181/401
6
108/319
6
119/412
Summary %
(95% CI; I2)
44
(36-52; 61)
35
(23-49; 83)
23
(12-37; 89)
Low risk of bias
N of studies
N obs/N att
5
653/1176
3
275/1049
3
181/1049
Summary %
(95% CI; I2)
45
(33-58; 88)
35
(21-51; 89)
20
(12-30; 76)
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Loss to follow-up summary estimates varied highly according to the study design. 
Loss to follow-up rates were consistently around 10% in prospective cohort studies 
most likely reflecting a real-life clinical situation. 
5.2.1 S5 IN OUTCOME PREDICTION OF UNTREATED CIN2 
In the prospective cohort study of 149 young women (study III) with untreated, 
histologically confirmed CIN2, outcome rates were in line with the findings of the 
meta-analysis (study II), although follow-up is still ongoing for 63 of the women 
(42%) (Figure 3). Eighty-eight of the women regressed to <CIN1 (59%), 25 
progressed to ≥CIN3 (17%), and 36 persisted as CIN1/2 (24%). The women’s mean 
age was 26.0 years, 52% (67/128) were current cigarette smokers, and 82% 
(116/141) were positive for any hrHPV genotype on the baseline visit. Overall, the 
most common HPV genotypes were HPV16 (43%, 61/141), HPV31 (13%, 19/141), 
HPV18 (8%, 11/141), and HPV33 (6%, 8/141). The baseline characteristics of the 
women did not differ statistically between the outcome categories (regression, 
persistence, progression) except for any hrHPV genotype positivity between the 
regression and persistence categories. 
 
In a multivariable model, the odds ratios (OR) of the S5 classifier in different 
outcomes showed the S5 classifier to be an independent predictor of outcomes 
when adjusted for HPV16/18/31/33-status, initial cytology, cigarette smoking, and 
age among the regression versus progression group (crude OR 1.17, 95% CI 1.06-
1.30; adjusted OR 1.12, 95% CI 1.00-1.27). 
 
When comparing odds ratios for S5 results (high-tertile and >0.8 cut-offs) between 
different outcome categories, the highest OR of 4.84 was reached in the comparison 
of regression versus progression with the high-tertile cut-off (Table 14). The 
corresponding area under the curve (AUC) from the >0.8 S5 classifier cut-off was 
0.718. Nearly all outcome comparisons reached statistical significance. 
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Table 14. S5 classifier high-tertile and 0.8 cut-off odds ratios (OR) and area under the receiver 
operating characteristic curve (AUC) with 95% confidence intervals (95% CI) in different 
outcome comparisons of untreated CIN2. Significant results in bold. AUC for S5 at the 
>0.8 cut-off. 
 
 
When comparing ORs for progression and persistence, with regression as the 
referent group, high-tertile S5 positivity was found to be a significant prognostic 
variable (OR 3.39, 95% CI 1.35-8.50), whereas HPV16/18 genotyping positivity was 
not (Table 15). Additional analyses associated HPV16/18/31/33 positivity with 
persistence (OR 3.50, 95% CI 1.44-8.52) and also to progression to a slightly lesser 
extent (OR 3.17, 95% CI 1.15-8.68). 
Table 15. Odds ratios (OR) for outcomes with regression as the referent group with S5 high-tertile 
positivity and HPV16/18 genotyping positivity  
 
 
Clinical outcome 
comparison
High-tertile S5
OR (95% CI)
0.8 cut-off S5
OR (95% CI)
0.8 cut-off S5
AUC (95% CI)
Regression 
vs. persistence
2.61 (1.03-6.61) 1.04 (0.95-1.14) 0.567 (0.46-0.68)
Regression 
vs. progression
4.84 (1.35-17.41) 1.17 (1.06-1.30) 0.718 (0.61-0.83)
Persistence
vs. progression
2.86 (0.88-9.33) 1.15 (1.01-1.30) 0.676 (0.54-0.82)
Regression/persistence
vs. progression
4.48 (1.27-15.77) 1.16 (1.06-1.28) 0.706 (0.60-0.81)
Regression 
vs. persistence/progression
2.68 (1.27-5.64) 1.10 (1.02-1.19) 0.630 (0.54-0.72)
Outcome
S5 high-tertile
OR (95% CI)
HPV16/18 positivity
OR (95% CI)
Regression 1.00 Ref 1.00 Ref
Persistence 1.33 (0.58-3.07) 1.99 (0.91-4.35)
Progression 3.39 (1.35-8.50) 2.38 (0.96-5.91)
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The performance of the S5 classifier alone and in combination with other possible 
predictive markers was tested in different outcome comparisons. The highest AUC 
was 0.735 (95% CI 0.621-0.849) when comparing regression with progression and S5 
>0.8 and cytology ≥HSIL was regarded as positive. Combining HPV16/18 genotyping 
positivity provided no additional advantage (Figure 7).  Addition of HPV16/18/31/33 
genotyping also did not provide additional advantage with the exception of 
comparison of regression vs. persistence/progression (AUC of 0.666, 95% CI 0.580-
0.752). 
 
Figure 7 Receiver-operating characteristic (ROC) curves for the performance of S5-classifier alone 
and in combination with other tests in different clinical outcome categories. The points 
0.00 and 1.00 are for the ROC start and end points for the single tests. Redrawn from 
Louvanto et al. Clin Infect Dis. 2019 Jul 25. doi: 10.1093/cid/ciz677 
5.3 TREATMENT OF VAIN 
Study IV included 30 women (median age 54, range 31-82) with histologically 
confirmed vaginal HSIL. Half of the women had been previously treated for one or 
multiple HPV-related genital diseases: 37% (11/30) for VAIN, 23% (7/30) for CIN, 13% 
(4/30) for cervical cancer (over five years ago) and 10% (3/30) for VIN. Four patients 
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were diagnosed with concomitant CIN1 and one with VIN3. Eleven women (37%) had 
previously had a hysterectomy, and seven (23%) were current cigarette smokers. 
 
At baseline 25 women had VAIN2 (83%), and five had VAIN3 (17%). Four of the 
women with VAIN3 were in the imiquimod arm, while none were in the laser arm. 
Multifocal VAIN was found in 63% (19/30) of the women. At baseline 77% (20/26) 
were found to be hrHPV positive. No significant differences existed between the 
study arms by any of the baseline characteristics or findings. 
 
None of the lesions progressed during the 16 weeks of follow-up. No differences 
were seen in the histological regression rates between the arms (Table 17). hrHPV 
clearance at the end of the study was significantly higher in the imiquimod arm at 
63% when compared to 11% of the laser arm (p=0.05). One patient in the expectant 
management arm died during the study period due to unrelated causes (lung cancer), 
and four were treated conventionally (laser vaporisation) on request. Three of the 
five untreated patients had complete histological regression at the end of the study.  
 
None of the women discontinued the imiquimod treatment, but one halved the dose. 
All women, however, reported adverse effects from the treatment. Flu-like 
symptoms (including a rapidly subsiding fever up to 39° Celsius within 12 hours of 
imiquimod application for four women) were reported by 9/10 women, local 
irritation of the vagina and vulva by 6/10, and lower abdominal pain by 3/10. None 
needed immediate evaluation for the symptoms, which were alleviated with 
paracetamol or NSAID medication. Vulvar irritation was seen in two women at 
intermediate study visits and were treated with local estrogen cream. One woman 
had a vulvar ulceration at the intermediate study visits, but this had healed by the 
end of the study. 
 
 
 
 
 
 75 
Table 16. Histological and hrHPV end of study results from the randomised trial of VAIN 
treatment 
 
1 Analyses between imiquimod and laser arms (none of the analyses between two other individual arms 
reached statistical significance); 2 defined as <VAIN1; 3 defined as VAIN1; 4 n=number cleared or 
persisted; N=number of total tested both at baseline and at 16 weeks 
 
Imiquimod
(N=10)
Laser
(N=10)
Expectant 
management
(N=9)
p-value 1
Histology N % N % N %
Regression of disease (any) 8 80 10 100 6 67 0.474
Complete regression 2 7 70 9 90 4 44 0.582
Partial regression 3 1 10 1 10 2 22 0.721
Persistent disease 2 20 0 0 3 33 0.474
hrHPV status 4 n/N % n/N % n/N %
Cleared HPV 5/8 63 1/9 11 1/6 17 0.05
Persistent HPV 3/8 38 6/9 67 3/6 50 0.437
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6 DISCUSSION  
6.1 HPV IN CERVICAL AND VAGINAL PRECANCEROUS DISEASE 
HPV infection is recognised as a necessary factor in the carcinogenic processes of the 
cervix and vagina (zur Hausen, 1977; Walboomers et al., 1999; Arbyn, de Sanjosé, et 
al., 2012). Study I found that, overall, 83% (1058/1279) of women with abnormal 
cytology were positive for any HPV genotype at colposcopy when referred according 
to guidelines aiming to find all relevant disease while omitting common transient 
infections. Over two thirds (>900) of the women in study I were positive for hrHPV 
genotypes, including a third for HPV16/18. Low-risk genotypes were only found in 
approximately 10%. The distribution of high- and low-risk genotypes in study I 
followed well-recognised patterns, since the proportion of hrHPV-related disease 
increases with the severity of findings (Guan et al., 2012). 
 
Over 90% of women diagnosed with histological HSIL+ were positive for hrHPV 
genotypes, including over half for HPV16/18 (study I). Among young women with 
CIN2 (study III), 82% were positive for any hrHPV genotype and approximately half 
for HPV16/18 within one to two months of the histological CIN2 diagnosis. An 
American study made a similar finding of approximately half of CIN2 in young women 
being attributed to HPV16/18 (Moscicki et al., 2010). Study IV found that 77% of 
women with high-grade VAIN were hrHPV positive within 1-2 months of the 
histological diagnosis, which is in line with previous reports (Gunderson et al., 2013; 
Rhodes, Chenevert and Munsell, 2014; Jentschke et al., 2016). 
 
HPV16 was the most commonly observed genotype (28.3%) in study I, as expected 
(Bruni et al., 2010; Leinonen et al., 2013). HPV52 has distinct geographical prevalence 
patterns, with it being among the most common genotypes in Denmark, Eastern 
Europe, Africa and Asia and, according to a previous study, also in Finland (Kjaer et 
al., 2008; Bruni et al., 2010; Leinonen et al., 2013). Our study confirms the finding 
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regarding Finland. However, HPV52 is more uncommon in the rest of Europe (Bruni 
et al., 2010).  
 
Samples tested for HPV (genotyping or hrHPV testing) from the prospective studies 
were obtained one to six months after the initial cytological diagnosis (study I) or 
within one to two months of histological diagnosis (studies III and IV). This could have 
allowed time for HPV clearance, because a small proportion of high-grade disease 
was found to be HPV negative via either genotyping or hrHPV testing (Ho et al., 1998). 
The women in study III and IV also had punch biopsies taken prior to recruitment that 
can promote disease regression (Trimble et al., 2005; Mark et al., 2019). Genotyping 
detects more HPV genotypes and is more sensitive than commercial hrHPV tests, 
which have higher thresholds for positive results aimed at finding only clinically 
relevant disease (Meijer et al., 2009).  
6.1.1 EFFECT OF AGE ON HPV GENOTYPE DISTRIBUTION 
 
HPV16/18 is found in approximately 70% of cervical cancers globally (de Sanjose et 
al., 2010; Guan et al., 2012). Age-specific HPV genotype distribution has been mostly 
described in women with normal cytology, in screening populations, and in women 
with cervical cancer (Franceschi et al., 2006; de Sanjose et al., 2013). Data on age-
specific HPV genotype distribution in histological HSIL, however, are relatively sparse. 
Our study found HPV genotype distribution in highly screened women with abnormal 
cytology warranting colposcopy to be distinctly polarised by age. All hrHPV genotypes 
were more uncommon with advancing age, but the decrease was most pronounced 
for HPV16. Conversely, the proportion of women found HPV negative in genotyping 
increased with advancing age.  
 
A similar age-related pattern remained even when assessing only the women with 
histological high-grade cervical disease. The pattern remained when separating high-
grade squamous histologies (CIN2 and CIN3+) and glandular abnormalities (AIS+). In 
all high-grade disease categories, however, the proportion of disease attributed to 
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other high-risk genotypes than HPV16/18 was greater with advancing age, and it is 
notable that the median age of the women in the ≥45 years of age group in study I 
was only 51. The proportion of HPV genotyping negative high-grade disease also 
increased markedly in the oldest age-group. 
 
Our finding is consistent with a few reports on age-specific genotype distribution in 
primarily cervical cancer when invasive cancers related to HPV16/18 were diagnosed 
at a younger age (Wheeler et al., 2009; Carozzi et al., 2010; Brotherton et al., 2017). 
An American study including CIN3 and AIS showed no age-specific pattern in those 
histological entities but did see one in invasive cervical cancer in samples retrieved 
from 1980 to 2000 (Wheeler et al., 2009). The study also noted that the overall 
proportion of disease attributed to HPV16 had declined over the past decades, while 
other hrHPVs — excluding HPV18 — had become more common. Our more recent 
study could have affected the differing results regarding CIN3 and AIS. The observed 
time trend in genotype distribution in the American study might also be linked to 
participation in cervical cancer screening as the authors themselves noted. Women 
in Finland are, in general, highly screened, because the organised nationwide 
screening program started in the 1960s, and 90% of women currently have a smear 
within every five years either within the organised program or opportunistically 
(Working group set by National Institute for Health and Welfare (THL), 2011). 
 
The core reason for this polarisation of genotypes in high-grade cervical disease 
remains unclear based on these and previous data. In addition to differing screening 
attendance rates, it may be caused by a longer sojourn period before high-grade 
disease with genotypes other than HPV16/18 appear (Wheeler et al., 2009). Another 
explanation might be latent HPV infections re-activating with menopausal immune 
senescence (Castle et al., 2005). Of note, the prevalence of HPV18 in study I showed 
only a small reduction with advancing age (7.1% in women <30 and 4.6% in women 
≥45). It has been suggested that HPV18-related disease is not as easily detected in 
cytology-based screening as is HPV16-related disease (Khan et al., 2005). 
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We found the rate of HPV-negative, high-grade cervical disease to be low, as 
expected (3.4%, 17/503); however, the rate increased with advancing age up to 6.5% 
in women over 45 years of age. A recent large study on invasive cervical cancers from 
Sweden found only 80% to be HPV positive in genotyping (Lei et al., 2018). Their 
study associated HPV negativity with older age at diagnosis. These findings raise 
questions on the accuracy of hrHPV-based screening in older women. Sweden is 
currently cotesting (hrHPV test and cytology) approximately 41-year-old women who 
have not previously been screened with an hrHPV test (Cervixcancerprevention: 
Nationellt vårdprogram och konsekvenser av införande av Socialstyrelsens 
rekommendationer gällande screening juni 2015, no date).  
 
Finding an even more efficient screening and triage algorithm is highly important 
despite the great success of cytology-based cervical cancer screening programs. 
Screening based on hrHPV testing has increased the sensitivity of screening when 
compared to cytology (Koliopoulos et al., 2017). Nevertheless, a problem remains 
with the decreased specificity, setting great demands on the triage test. Cytology 
triage is currently implemented in Finland (Veijalainen et al., 2016). A recent study 
from the United States showed p16/Ki67 dual staining to be able to reduce 
colposcopy referral rates by approximately 30% (Wentzensen et al., 2019). Using 
HPV16/18 genotyping to decide on the urgency of colposcopy in hrHPV-positive 
women has also been suggested, but studies assessing the method were not 
analysed in separate age strata (Castle, Stoler, et al., 2011; Stoler et al., 2011). In light 
of our data, high-grade cervical disease related to HPV16/18 was more uncommon 
than disease related to other high-risk genotypes in women ≥45 years of age, raising 
questions about the appropriateness of HPV16/18 genotyping as a triage test, at 
least in highly screened populations. 
 
Taking into account the recent findings of genotype distribution and HPV negativity 
in the cervical cancer of older women, these data should not be overlooked when 
applying any adjunctive screening technologies. Prophylactic vaccinations will also 
greatly reduce the sensitivity of screening, but for decades there will still be 
Discussion 
80 
unvaccinated women also attending screening programs. The decision made in 
Sweden to cotest women in their 40s who have not been previously screened with a 
hrHPV test seems valid based on our findings. Cotesting with dual staining could 
possibly further improve sensitivity, and methylation can possibly replace this in the 
future, if sufficient evidence is accumulated. 
 
The effect of prophylactic HPV vaccinations in a real-life setting is currently being 
seen in women in their 20s in countries that adopted the vaccination into national 
programs early on (Kavanagh et al., 2017; Garland et al., 2018; Palmer et al., 2019). 
A steep decline is evident in at least HPV16/18 prevalence and related precancerous 
lesions. This phenomenon will most likely be seen in all regions with sufficient vaccine 
coverage. Decade-long efficacy in cancer prevention is very likely based on current 
findings but will only be seen much later. Moreover, it is not yet known how long 
lasting cross-protective efficacy against other hrHPV genotypes will be for the 
bivalent or quadrivalent vaccines (Artemchuk et al., 2018). The polarisation of 
genotype distribution by age observed in study I does not inform us on when the 
women in the oldest age group have acquired the hrHPV genotypes, other than 
HPV16/18 that were more common in HSIL+ cases. Therefore, it cannot be reliably 
deduced what the effect of prophylactic vaccination in adolescence will mean for 
women in their 40s or 50s despite a likely near-eradication of HPV16/18. 
Concurrently, at least in developed countries, exposure patterns to HPV can be 
expected to change, because monogamous, life-long relationships are not as 
common as in the past (Vaccarella et al., 2006; Bosch et al., 2008). 
6.2 OUTCOMES OF UNTREATED CIN2 WITH REGARD TO AGE 
Our meta-analysis of the clinical course of untreated, histologically confirmed CIN2 
(study II) was able to show an age-specific pattern of more frequent regression and 
less frequent progression in younger women (<30 years of age). This finding confirms 
the adequacy of some treatment guidelines already suggesting active surveillance as 
an alternative for immediate treatment for CIN2 in young women (Massad et al., 
2013). Study I found that the burden of high-grade preinvasive cervical disease (CIN3 
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and AIS) was in women 30-44.9 years of age (151/245 cases), but the burden of CIN2 
was in women <30 (95/238 cases), highlighting the importance of the issue of CIN2 
management. 
 
Of most concern in CIN2 active surveillance protocols is the risk of progression to 
invasive cervical cancer. The studies included in the meta-analysis showed 
progression to invasive disease to be mostly associated with older age and longer 
follow-up. The majority of invasive disease (n=11/15) was reported from a single 
Japanese study in which none of the cases of invasive disease were diagnosed in 
women under the age of 30 (Hosaka et al., 2013). Age at diagnosis could not be 
determined for the remaining four cases from the original publications. The majority 
of cases of AIS diagnosed during the active surveillance of untreated CIN2 (n=14/15), 
however, were found in young women under age 25 (Loopik et al., 2016; Munro et 
al., 2016). Loss to follow-up is another concern of active surveillance, but it is 
reassuring that the 10% loss seen in the prospective studies of meta-analysis most 
likely best reflects a real-life situation. 
 
When comparing the reported natural history of CIN3 to the finding of our meta-
analysis, a 0.5% progression to invasion rate for CIN2, the natural histories of these 
two CIN grades appear to be very different (McCredie et al., 2008). Progression to 
invasion for CIN3 was reported to be 17% at 5 years and 34% at 20 years in the New 
Zealand study (McCredie et al., 2008). Our finding raises questions on the 
appropriateness of combining CIN2 and CIN3 as histological HSIL in the updated WHO 
classification (WHO, 2014). It is widely accepted that CIN3 should be treated, and the 
new histological HSIL can hinder a more personalised approach in CIN2’s 
management. However, the long-term risk of recurrent disease in women with 
regressed CIN2 initially managed with active surveillance is not currently confirmed. 
 
The findings of the meta-analysis are important, especially for very young women, as 
they are the ones most likely to plan future pregnancies and have the greatest 
likelihood of spontaneous disease regression and the least risk of progression. The 
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combination of this and the negative impact of local CIN treatments have been 
shown to have on future pregnancies (Kyrgiou et al., 2016, 2017) justify consideration 
of active surveillance, at least in selected young women. Shared decision making with 
the patient and appropriate information on the risks of both active surveillance and 
treatment are of key importance.  
 
Active surveillance may increase costs and demands on health care services, since 
more visits and testing most likely are needed than if a woman is treated and re-seen 
for a test of cure. CIN2 cases persisting beyond two years most likely should be 
treated, as progression was seen to increase with time, according to our results. A 
firm recommendation for an active surveillance protocol is difficult to provide, 
because follow-up protocols of studies included in the meta-analysis varied highly. 
The most common follow-up in prospective low-risk of bias studies, however, was 
colposcopy every three to four months with cytology and routine punch biopsies or 
punch biopsies if progression was suspected. 
6.3 S5 CLASSIFIER IN OUTCOME PREDICTION OF CIN2 
When considering an individual woman with CIN2, active surveillance instead of 
immediate treatment always bears the risk of disease progression despite adhering 
to a follow-up protocol. A predictive biomarker for outcomes could aid clinical 
decision making in the future and change the outline of active surveillance protocols 
of CIN2, because cases with risk of progression could be treated immediately and 
cases with low risk could be managed expectantly. Our study (study III) is, to our 
knowledge, the first to show DNA methylation to be able to independently predict 
the risk of progression of untreated, high-grade cervical disease in a longitudinal 
study. 
 
Other biomarkers have also been tested as progression markers for untreated CIN2. 
p16 has been found to be inconsistent in two studies (Guedes et al., 2007; Omori et 
al., 2007). A previous study has also shown baseline HPV16/18 positivity to perform 
relatively poorly in outcome prediction of CIN2 in young women (Moscicki et al., 
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2010). However, persisting hrHPV (the same genotype found in consecutive samples) 
was more closely associated with persistence or progression in that study. Our meta-
analysis (study II), although based on a small number women, shows that only 25% 
of baseline HPV16/18-positive and 21% of baseline hrHPV-positive women with CIN2 
experienced progression at two years. Our study III shows that baseline 
HPV16/18/31/33 positivity was associated with persistence of CIN2 and even 
progression, although it did not predict it quite as well as the S5 classifier. 
 
DNA methylation of many different candidate genes of both HPV and the host have 
previously been shown to be able to differentiate between different CIN grades and 
invasive cancer (Mirabello et al., 2012, 2013; Wentzensen et al., 2012; Kalantari et 
al., 2014; Louvanto et al., 2015; Clarke et al., 2017). Methylation of other candidate 
genes and also the S5 classifier have previously been shown to be able to predict 
high-grade cervical disease in hrHPV-positive women (Brentnall et al., 2014; De 
Strooper et al., 2014; Lorincz et al., 2016). Our study demonstrates the ability of the 
S5 classifier also to differentiate between progressive and regressive high-grade 
cervical disease. The S5 classifier, in contrast to DNA methylation tests of host genes, 
has not shown improved sensitivity when combined with HPV16/18 genotyping (De 
Strooper et al., 2014; Lorincz et al., 2016; Cook et al., 2018). HPV16/18 genotyping 
did not add any additional advantage in our current study, either.  
 
CIN histological grading suffers from interobserver variability (Ismail et al., 1989; 
Stoler and Schiffman, 2001), so having a well-performing predictive biomarker for 
preinvasive cervical disease overall could even make further histological grading  
beyond “CIN” unnecessary. Based on our meta-analysis (study II) and a previous 
study from New Zealand, the natural histories of CIN3 and CIN2 appear to be very 
different (McCredie et al., 2008). Still, even the majority of untreated CIN3 lesions do 
not progress to invasive cancer, opening a possibility of expectant management in 
cases of CIN3 if outcomes could be reliably predicted. A predictive test of CIN 
outcomes could also save costs due to the likely need for fewer follow-up visits. 
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6.4 IMIQUIMOD IN TREATMENT OF VAIN 
Treatment of VAIN is burdensome for both patients and caregivers. Recurrences are 
common, and repeated surgical and laser treatments can especially be mutilating 
through vaginal scarring (Perrotta et al., 2013; Wang et al., 2014; Jentschke et al., 
2016; Kim, Lee and Lee, 2018). A treatment targeting the cause (hrHPV) of VAIN 
instead of the outcome (mucosal lesions) could be beneficial. Imiquimod activates 
the local immune response by cytokine release and dendritic cell activation, resulting 
in activation of both innate and acquired immunity (Schon and Schon, 2007). 
Imiquimod is topically used to treat external genital warts. The imiquimod dosage 
and delivery system used in our study was the same as used in an Austrian study 
exploring the use of imiquimod in high-grade CIN treatment, in which they observed 
a 73% regression rate compared to 39% with placebo (Grimm et al., 2012). 
Imiquimod has also shown very promising results in VIN treatment (van Seters et al., 
2008). These facts make it also an attractive option for treatment of VAIN. 
 
Study IV’s study population was similar to those of previous VAIN treatment studies 
(Gunderson et al., 2013; Rhodes, Chenevert and Munsell, 2014). Our study showed 
equal short-term (16-week) efficacy of vaginal imiquimod to conventional laser 
vaporisation in histological regression rates. However, the hrHPV clearance rate in 
the imiquimod group was higher, possibly leading to a promise of lower recurrence 
rates, since hrHPV persistence has been shown to be a risk factor (Frega et al., 2007; 
Hee Seung Kim et al., 2009; Wang et al., 2014; Jentschke et al., 2016). Of note, three 
out of five women in the expectant management group had complete histological 
regression at the end of the study period, while the remaining two had persisting 
VAIN2. The most plausible explanation for the regression appears to be the punch 
biopsies taken for the initial diagnosis. 
 
Imiquimod treatment had short-term adverse effects in all women using it. None of 
the women discontinued treatment despite the adverse effects. Many women in 
study IV had recurrent VAIN, making them highly motivated to try a new treatment. 
All current treatments of VAIN also have adverse effects. A self-administered medical 
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treatment might be found more attractive by some in comparison to surgical or laser 
treatment. It is also possible that multifocal disease could be better treated with 
vaginal suppositories. A new treatment option could well be welcomed by both 
patients and caregivers. 
 
6.5 STRENGTHS AND WEAKNESSES 
The results in study I should be generalisable, because the women came from an 
unselected population referred to the single referral colposcopy centre in the 
Helsinki metropolitan area that serves a population base of approximately one 
million people. Only a small number of genotyped samples in study I were found to 
be invalid or were not taken in (n=23/1302), and HPV genotyping was performed at 
an international reference laboratory; thus, missing data should not have a major 
effect on our results. Study participants were referred to colposcopy according to 
Finnish Current Care Guidelines, so the observed hrHPV distribution should reflect 
the genotypes causing clinical morbidity, omitting most transient infections.  
 
A weakness of study I is that the results cannot be used to assess distribution of 
hrHPV in the whole population. Study participants were asked whether they have 
been vaccinated for HPV, but this could not be confirmed elsewhere, which might 
introduce recall bias. The data on vaccination status were not necessarily recorded 
in patient records. Most likely the number of vaccinated women in the study is very 
low, since they could not have been vaccinated as a part of the national program that 
started only in 2013. Another shortcoming of the study is the low number of invasive 
cancer cases and individual hrHPV infections, excluding HPV16. Most invasive 
cervical cancer cases were diagnosed in women ≥45 (9/20 cases), which is in line with 
the mean age of cervical cancer diagnosis (45 years) in Finland (Finnish Cancer 
Registry, no date). 
 
The regression rates in study II were high even at the most conservative estimates 
and despite the great observed heterogeneity in the summary estimates. The 
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observed interstudy heterogeneity that was not reduced in sensitivity and subgroup 
analyses is most likely related to the inherent difficulty in the histological 
classification of CIN (Ismail et al., 1989; Stoler and Schiffman, 2001). The meta-
analysis could not take the lesions’ clinical features into account (type of 
transformation zone, lesion size), which most likely would also affect outcomes and 
should be considered in clinical practice. A strength of the study is the comprehensive 
literature search and duplicate evaluation performed at all stages. The meta-analysis 
is, to our knowledge, the first to be performed on histological CIN2 natural history. A 
most often cited previous review on CIN natural history included cytological 
diagnoses of CIN. It included neither a weighted meta-analysis nor took into account 
the length of follow-up or the age of the women (Östör, 1993).  
 
The strengths of study III include the study’s novelty, the unique study population, 
the rigorous follow-up scheme the women adhered to, and the re-assessment of the 
initial histological CIN2 diagnosis. Only a small proportion of endocervical cell 
samples were missing (n=8/149). Overall, the loss to follow-up rate in the study is 
extremely low (data not included in the current publication). The S5 classifier was 
rigorously assessed against different possible progression markers to minimise bias 
according to the REMARK guidelines (McShane et al., 2006). A weakness of our 
current study is that the women who have not completed the 24 months of follow-
up (63/149, 42%) and are now classified as regressed or persisting might switch 
outcome categories over time, e.g., a case classified as persistence might regress or 
progress eventually. The study was also restricted to young women and the uniform 
histological diagnosis of CIN2, making the generalisability of the results to women of 
all ages and other CIN grades uncertain. 
 
In study IV a weakness of the proof of principle pilot study is the small sample size 
(n=30) and the short length of follow-up (4 months). The study design was decided 
upon because previous data on imiquimod treatment of VAIN were scarce, and 
power calculations could not be performed. The randomised study design can be 
considered a strength as previous studies using imiquimod have been non-
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randomised introducing most likely selection bias. Moreover, the largest previous 
study on imiquimod treatment of VAIN, which included 56 young women (median 
age 20), used primarily only colposcopy for diagnosis and follow-up without 
histological confirmation (Buck and Guth, 2003). A second published study on 
imiquimod treatment of high-grade VAIN had only seven subjects but a mean follow-
up of 18 months (range 5-31 months) (Haidopoulos et al., 2005). hrHPV clearance 
was not assessed in either of the previous studies.  
 
The women in study IV adhered well to the study protocol with no losses to follow-
up except one death due to unrelated causes. The women were also highly 
compliant, though 4/10 women in the expectant management arm requested laser 
vaporisation during the study period. The women were also rigorously examined 
with colposcopy, cytology, histology, and hrHPV testing. However, hrHPV test results 
at baseline and/or the end of study were missing from 7/30 patients, and hrHPV 
clearance could not be assessed. The hrHPV test used was switched during the study 
period from Hybrid Capture 2 to Aptima, which might have somewhat impacted the 
results, since some women might have initially been tested with Hybrid Capture 2 
and followed-up with Aptima. The imiquimod arm had 4/10 women with VAIN3 and 
the laser arm none, which might have biased the results.  
 
6.6 FUTURE IMPLICATIONS 
The reason for the age-specific polarisation of HPV genotypes would be of clinical 
interest. This information could aid estimating the long-term efficacy of the 
prophylactic HPV vaccines and help design future screening policies. It is possible that 
the polarisation is mostly due to screening, since it appears that HPV16-related 
disease is most easily detected. Latent infections as such and in combination with 
immune senescence offer another plausible explanation. We did not analyse data on 
previous abnormal cytology, previous CIN treatments, or sexual habits and history in 
study I.   
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A randomised trial comparing active surveillance with local treatment is called for 
despite the reassuring finding of our meta-analysis on outcomes of untreated CIN2. 
Long term follow-up results of actively surveilled and regressed CIN2 cases is also of 
great interest, because the recurrence rate remains unknown. It is important to bear 
in mind, despite the lack of data, that recurrences after local treatment do also occur 
both in the short and long term.  
 
DNA methylation presents an interesting option for biomarker development for CIN 
outcomes. Overall, methylation research is still in its early stages, and refinement of 
genes of interest and combinations of them is called for. The S5 classifier comprising 
both a host gene and several hrHPV genotype genes seems to be currently 
performing better than methylation tests solely testing host genes. If study III’s 
results can be replicated, that could change the outline of active surveillance 
protocols for CIN2 and perhaps even CIN on a broader scope. Further refinement of 
the DNA methylation assays is also a priority (Lorincz, 2016). Changes in methylation 
during follow-up of high-grade CIN could also be of interest.  
 
Imiquimod presents an interesting option in treatment of HPV-related genital 
disease, which has historically been mostly surgical or destructive. The results from 
our randomised proof of principle pilot study on VAIN treatment are very preliminary 
and need to be validated in a larger group of patients with longer follow-up. If 
imiquimod would prove to be non-inferior to laser vaporisation, the current 
treatment of choice, it would provide a welcome alternative to repeated treatments 
in cases of recurrence. The optimal dose of imiquimod and treatment length need to 
be further explored, as well as the possibility of repeated imiquimod treatments.  
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7 CONCLUSIONS 
The following conclusions can be drawn from this thesis 
 
 
 
1. Current and future screening strategies should take into account the uneven 
distribution of HPV16/18-related high-grade cervical disease according to age 
in highly screened women. 
 
2. Active surveillance instead of immediate treatment of CIN2 can be justified in 
selected young women who are willing to adhere to monitoring and whose 
personal preference, after adequate information on risks, is active 
surveillance. 
 
3. The S5 DNA methylation classifier was able to differentiate between 
regressive and progressive CIN2. DNA methylation as a predictive biomarker 
for outcomes of cervical preinvasive disease should be further investigated 
and validated. 
 
4. Self-administered imiquimod treatment may have potential as an efficacious 
option for laser vaporisation in high-grade VAIN, provided further studies 
show positive long-term results. 
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